
Phenobarbital	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
dyskinesia	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
neurologically	ADV	O	B-Entity
-	PUNCT	O	I-Entity
impaired	ADJ	O	I-Entity
child	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
results	NOUN	O	O
are	VERB	O	O
discussed	VERB	O	O
in	ADP	O	O
view	NOUN	O	O
of	ADP	O	O
a	DET	O	O
primary	ADJ	O	O
action	NOUN	O	O
of	ADP	O	O
calcitonin	NOUN	O	O
on	ADP	O	O
the	DET	O	O
striatonigral	ADJ	O	O
GABAergic	PROPN	O	O
pathway	NOUN	O	O
mediating	VERB	O	O
the	DET	O	O
DA	NOUN	O	I-Entity
-	PUNCT	O	O
related	VERB	O	O
behavioral	ADJ	O	O
messages	NOUN	O	O
of	ADP	O	O
striatal	ADJ	O	O
origin	NOUN	O	O
.	PUNCT	O	O

Male	PROPN	O	O
F344	PROPN	O	O
rats	NOUN	O	O
,	PUNCT	O	O
5	NUM	O	O
weeks	NOUN	O	O
of	ADP	O	O
age	NOUN	O	O
,	PUNCT	O	O
were	VERB	O	O
maintained	VERB	O	O
on	ADP	O	O
diet	NOUN	O	O
containing	VERB	O	O
1%	NUM	O	O
or	CCONJ	O	O
2%	NUM	O	O
BHA	NOUN	O	I-Entity
by	ADP	O	O
weight	NOUN	O	O
and	CCONJ	O	O
simultaneously	ADV	O	O
on	ADP	O	O
drinking	NOUN	O	O
water	NOUN	O	O
supplemented	VERB	O	O
with	ADP	O	O
RA	PROPN	O	I-Entity
at	ADP	O	O
various	ADJ	O	O
concentrations	NOUN	O	O
(	PUNCT	O	O
w	PROPN	O	O
/	SYM	O	O
v	PUNCT	O	O
)	PUNCT	O	O
for	ADP	O	O
52	NUM	O	O
weeks	NOUN	O	O
.	PUNCT	O	O

Rats	NOUN	O	O
that	ADJ	O	O
received	VERB	O	O
ketanserin	NOUN	O	I-Entity
and	CCONJ	O	O
alfentanil	NOUN	O	I-Entity
exhibited	VERB	O	O
less	ADV	O	O
rearing	NOUN	O	O
and	CCONJ	O	O
exploratory	ADJ	O	O
behavior	NOUN	O	O
at	ADP	O	O
the	DET	O	O
end	NOUN	O	O
of	ADP	O	O
the	DET	O	O
60-min	NOUN	O	O
recording	NOUN	O	O
period	NOUN	O	O
than	ADP	O	O
did	VERB	O	O
animals	NOUN	O	O
that	ADJ	O	O
received	VERB	O	O
ketanserin	ADV	O	I-Entity
alone	ADV	O	O
.	PUNCT	O	O


-DOCSTART- (1545575)


METHODS	NOUN	O	O
:	PUNCT	O	O
We	PRON	O	O
investigated	VERB	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
varying	VERB	O	O
the	DET	O	O
intraperitoneal	ADJ	O	O
infusion	NOUN	O	O
rates	NOUN	O	O
of	ADP	O	O
bupropion	NOUN	O	B-Entity
HCl	PROPN	O	I-Entity
120	NUM	O	O

mg	PROPN	O	O
/	SYM	O	O
kg	INTJ	O	O
,	PUNCT	O	O
a	DET	O	O
known	VERB	O	O
convulsive	ADJ	O	I-Entity
dose	NOUN	O	O
50	NUM	O	O
(	PUNCT	O	O
CD50	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
on	ADP	O	O
the	DET	O	O
incidence	NOUN	O	O
and	CCONJ	O	O
severity	NOUN	O	O
of	ADP	O	O
bupropion	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
convulsions	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
Swiss	ADJ	O	O
albino	ADJ	O	O
mice	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
number	NOUN	O	O
,	PUNCT	O	O
time	NOUN	O	O
of	ADP	O	O
onset	NOUN	O	O
,	PUNCT	O	O
duration	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
intensity	NOUN	O	O
of	ADP	O	O
the	DET	O	O
convulsions	NOUN	O	I-Entity
or	CCONJ	O	O
absence	NOUN	O	O
of	ADP	O	O
convulsions	NOUN	O	I-Entity
were	VERB	O	O
recorded	VERB	O	O
.	PUNCT	O	O

Since	ADP	O	O
2005	NUM	O	O
,	PUNCT	O	O
the	DET	O	O
10-min	NOUN	O	O
loading	VERB	O	O
dose	NOUN	O	O
of	ADP	O	O
our	ADJ	O	O
dexmedetomidine	NOUN	O	I-Entity
protocol	NOUN	O	O
increased	VERB	O	O
from	ADP	O	O
2	NUM	O	O
to	ADP	O	O
3	NUM	O	O
microg.kg(-1	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
infusion	NOUN	O	O
rate	NOUN	O	O
increased	VERB	O	O
from	ADP	O	O
1	NUM	O	O
to	ADP	O	O
1.5	NUM	O	O
to	PART	O	O
2	NUM	O	O
microg.kg(-1).h(-1	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

-DOCSTART- (16157917)

The	DET	O	O
mean	ADJ	O	O
highest	ADJ	O	O
BIS	PROPN	O	O
score	NOUN	O	O
corresponding	VERB	O	O
to	ADP	O	O
the	DET	O	O
inability	NOUN	O	B-Entity
to	PART	O	I-Entity
repeat	VERB	O	I-Entity
words	NOUN	O	I-Entity
was	VERB	O	O
81.5	NUM	O	O
(	PUNCT	O	O
95%	NUM	O	O
CI	NOUN	O	O
=	SYM	O	O
78.1	NUM	O	O
to	ADP	O	O
84.8	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
'	PUNCT	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
'	PUNCT	O	O
group	NOUN	O	O
had	VERB	O	O
significant	ADJ	O	O
glomerular	ADJ	O	B-Entity
and	CCONJ	O	I-Entity
tubular	ADJ	O	I-Entity
lesions	NOUN	O	I-Entity
,	PUNCT	O	O
depressed	ADJ	O	O
activities	NOUN	O	O
of	ADP	O	O
mtDNA	PROPN	O	O
-	PUNCT	O	O
encoded	VERB	O	O
NADH	PROPN	O	O
dehydrogenase	NOUN	O	O
and	CCONJ	O	O
cytochrome	NOUN	O	O
-	PUNCT	O	O
c	NOUN	O	O
oxidase	NOUN	O	O
(	PUNCT	O	O
COX	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
increased	VERB	O	O
citrate	ADJ	O	I-Entity
synthase	NOUN	O	O
activity	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
TD	PROPN	O	O
group	NOUN	O	O
,	PUNCT	O	O
three	NUM	O	O
patients	NOUN	O	O
developed	VERB	O	O
decreased	ADJ	O	B-Entity
auditory	ADJ	O	I-Entity
function	NOUN	O	I-Entity
,	PUNCT	O	O
of	ADP	O	O
which	ADJ	O	O
one	NUM	O	O
presented	VERB	O	O
with	ADP	O	O
an	DET	O	O
auditory	ADJ	O	B-Entity
loss	NOUN	O	I-Entity
of	ADP	O	O
-30	PROPN	O	O
dB	PROPN	O	O
,	PUNCT	O	O
whereas	ADP	O	O
in	ADP	O	O
the	DET	O	O
OD	PROPN	O	O
group	NOUN	O	O
only	ADV	O	O
one	NUM	O	O
patient	NOUN	O	O
presented	VERB	O	O
decreased	VERB	O	B-Entity
auditory	ADJ	O	I-Entity
function	NOUN	O	I-Entity
.	PUNCT	O	O

Posteroventral	ADJ	O	O
medial	ADJ	O	O
pallidotomy	NOUN	O	O
in	ADP	O	O
advanced	ADJ	O	O
Parkinson	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O

PILO	PROPN	O	I-Entity
-	PUNCT	O	O
injected	VERB	O	O
animals	NOUN	O	O
exhibited	VERB	O	O
NPY	PROPN	O	O
immunoreactivity	NOUN	O	O
in	ADP	O	O
the	DET	O	O
region	NOUN	O	O
of	ADP	O	O
the	DET	O	O
mossy	NOUN	O	O
fibre	NOUN	O	O
terminals	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
dentate	NOUN	O	O
gyrus	NOUN	O	O
inner	ADJ	O	O
molecular	ADJ	O	O
layer	NOUN	O	O
and	CCONJ	O	O
,	PUNCT	O	O
in	ADP	O	O
a	DET	O	O
few	ADJ	O	O
cases	NOUN	O	O
,	PUNCT	O	O
within	ADP	O	O
presumed	VERB	O	O
granule	ADJ	O	O
cells	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
determine	VERB	O	O
whether	ADP	O	O
myocardial	ADJ	O	O
contrast	NOUN	O	O
echocardiography	NOUN	O	O
performed	VERB	O	O
with	ADP	O	O
a	DET	O	O
stable	ADJ	O	O
solution	NOUN	O	O
of	ADP	O	O
sonicated	VERB	O	O
albumin	PRON	O	O
could	VERB	O	O
detect	VERB	O	O
regions	NOUN	O	O
of	ADP	O	O
myocardial	ADJ	O	O
underperfusion	NOUN	O	O
resulting	VERB	O	O
from	ADP	O	O
various	ADJ	O	O
degrees	NOUN	O	O
of	ADP	O	O
coronary	ADJ	O	B-Entity
stenosis	NOUN	O	I-Entity
.	PUNCT	O	O

Thallium-201	PUNCT	O	I-Entity

-DOCSTART- (1300436)

Renal	ADJ	O	B-Entity
failure	NOUN	O	I-Entity
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
weight	NOUN	O	B-Entity
loss	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
furosemide	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
group	NOUN	O	O
.	PUNCT	O	O

Within	ADP	O	O
the	DET	O	O
last	ADJ	O	O
several	ADJ	O	O
years	NOUN	O	O
,	PUNCT	O	O
previously	ADV	O	O
rare	ADJ	O	O
liver	NOUN	O	B-Entity
tumors	NOUN	O	I-Entity
have	VERB	O	O
been	VERB	O	O
seen	VERB	O	O
in	ADP	O	O
young	ADJ	O	O
women	NOUN	O	O
using	VERB	O	O
oral	ADJ	O	B-Entity
contraceptive	NOUN	O	I-Entity
steroids	NOUN	O	I-Entity
.	PUNCT	O	O

Loreclezole	PROPN	O	I-Entity
(	PUNCT	O	O
5	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
)	PUNCT	O	O
exerted	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
protective	ADJ	O	O
action	NOUN	O	O
in	ADP	O	O
amygdala	NOUN	O	O
-	PUNCT	O	O
kindled	VERB	O	O
rats	NOUN	O	O
,	PUNCT	O	O
reducing	VERB	O	O
both	DET	O	O
seizure	NOUN	O	I-Entity
and	CCONJ	O	O
afterdischarge	NOUN	O	O
durations	NOUN	O	O
.	PUNCT	O	O


The	DET	O	O
likelihood	NOUN	O	O
that	ADJ	O	O
bupropion	NOUN	O	I-Entity
induced	VERB	O	O
hepatotoxicity	NOUN	O	I-Entity
in	ADP	O	O
our	ADJ	O	O
patient	NOUN	O	O
was	VERB	O	O
possible	ADJ	O	O
,	PUNCT	O	O
based	VERB	O	O
on	ADP	O	O
the	DET	O	O
Naranjo	PROPN	O	O
probability	NOUN	O	O
scale	NOUN	O	O
.	PUNCT	O	O

Long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
oestrogen	NOUN	O	I-Entity
-	PUNCT	O	O
only	ADV	O	O
HT	PROPN	O	O
significantly	ADV	O	O
increased	VERB	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
venous	ADJ	O	B-Entity
thrombo	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
embolism	NOUN	O	I-Entity
,	PUNCT	O	O
stroke	NOUN	O	I-Entity
and	CCONJ	O	O
gallbladder	NOUN	O	B-Entity
disease	NOUN	O	I-Entity
(	PUNCT	O	O
after	ADP	O	O
one	NUM	O	O
to	ADP	O	O
two	NUM	O	O
years	NOUN	O	O
,	PUNCT	O	O
three	NUM	O	O
years	NOUN	O	O
and	CCONJ	O	O
seven	NUM	O	O
years	NOUN	O	O
'	PART	O	O
use	NOUN	O	O
respectively	ADV	O	O
)	PUNCT	O	O
,	PUNCT	O	O
but	CCONJ	O	O
did	VERB	O	O
not	ADV	O	O
significantly	ADV	O	O
increase	VERB	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
breast	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
conclusion	NOUN	O	O
,	PUNCT	O	O
where	ADV	O	O
succinylcholine	NOUN	O	I-Entity
is	VERB	O	O
used	VERB	O	O
,	PUNCT	O	O
lidocaine	NOUN	O	I-Entity
is	VERB	O	O
proven	VERB	O	O
to	PART	O	O
be	VERB	O	O
the	DET	O	O
useful	ADJ	O	O
pretreatment	NOUN	O	O
agent	NOUN	O	O
for	ADP	O	O
the	DET	O	O
reduction	NOUN	O	O
of	ADP	O	O
postoperative	ADJ	O	B-Entity
myalgia	NOUN	O	I-Entity
.	PUNCT	O	O

Clinical	ADJ	O	O
evaluation	NOUN	O	O
on	ADP	O	O
combined	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
oral	ADJ	O	O
prostacyclin	NOUN	O	I-Entity
analogue	NOUN	O	O
beraprost	NOUN	O	I-Entity
and	CCONJ	O	O
phosphodiesterase	NOUN	O	O
inhibitor	NOUN	O	O
cilostazol	NOUN	O	I-Entity
.	PUNCT	O	O

from	ADP	O	O
day	NOUN	O	O
7	NUM	O	O
to	ADP	O	O
14	NUM	O	O
,	PUNCT	O	O
CLZ	PROPN	O	I-Entity
:	PUNCT	O	O
200	NUM	O	O
mg	NUM	O	O
t.i.d	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
total	NOUN	O	O
of	ADP	O	O
4086	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
mean	VERB	O	O
age	NOUN	O	O
60.8	NUM	O	O
years	NOUN	O	O
)	PUNCT	O	O
diagnosed	VERB	O	O
with	ADP	O	O
RA	PROPN	O	I-Entity
were	VERB	O	O
enrolled	VERB	O	O
and	CCONJ	O	O
received	VERB	O	O
etoricoxib	ADJ	O	I-Entity
90	NUM	O	O
mg	X	O	O
daily	ADV	O	O
(	PUNCT	O	O
n	ADV	O	O
=	SYM	O	O
2032	NUM	O	O
)	PUNCT	O	O
or	CCONJ	O	O
diclofenac	NOUN	O	I-Entity
75	NUM	O	O
mg	NUM	O	O
twice	ADV	O	O
daily	ADV	O	O
(	PUNCT	O	O
n	ADV	O	O
=	SYM	O	O
2054	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

;	PUNCT	O	O
maximum	ADJ	O	O
)	PUNCT	O	O
duration	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
was	VERB	O	O
19.3	NUM	O	O
(	PUNCT	O	O
10.3	NUM	O	O
;	PUNCT	O	O
32.9	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
19.1	NUM	O	O
(	PUNCT	O	O
10.4	NUM	O	O
;	PUNCT	O	O
33.1	NUM	O	O
)	PUNCT	O	O
months	NOUN	O	O
in	ADP	O	O
the	DET	O	O
etoricoxib	NOUN	O	I-Entity
and	CCONJ	O	O
diclofenac	NOUN	O	I-Entity
groups	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

No	DET	O	O
significant	ADJ	O	O
differences	NOUN	O	O
were	VERB	O	O
observed	VERB	O	O
between	ADP	O	O
quetiapine	NOUN	O	I-Entity
and	CCONJ	O	O
placebo	NOUN	O	O
on	ADP	O	O
SAS	PROPN	O	O
and	CCONJ	O	O
BARS	PROPN	O	O
scores	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
bipolar	ADJ	O	B-Entity
mania	NOUN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
EPS	PROPN	O	I-Entity
,	PUNCT	O	O
including	VERB	O	O
akathisia	NOUN	O	I-Entity
,	PUNCT	O	O
with	ADP	O	O
quetiapine	NOUN	O	I-Entity
therapy	NOUN	O	O
is	VERB	O	O
similar	ADJ	O	O
to	ADP	O	O
that	DET	O	O
with	ADP	O	O
placebo	NOUN	O	O
.	PUNCT	O	O

Contribution	NOUN	O	O
of	ADP	O	O
the	DET	O	O
sympathetic	ADJ	O	O
nervous	ADJ	O	O
system	NOUN	O	O
to	ADP	O	O
salt	NOUN	O	O
-	PUNCT	O	O
sensitivity	NOUN	O	O
in	ADP	O	O
lifetime	NOUN	O	O
captopril	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
spontaneously	ADV	O	O
hypertensive	ADJ	O	I-Entity
rats	NOUN	O	O
.	PUNCT	O	O

Tri	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
ortho	PROPN	O	I-Entity
-	PUNCT	O	I-Entity
tolyl	ADJ	O	I-Entity
phosphate	NOUN	O	I-Entity
(	PUNCT	O	O
TOTP	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
360	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
,	PUNCT	O	O
po	INTJ	O	O
,	PUNCT	O	O
and	CCONJ	O	O
0,0'-diisopropyl	NUM	O	B-Entity
phosphorofluoridate	NOUN	O	I-Entity
(	PUNCT	O	O
DFP	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
1	NUM	O	O
mg	INTJ	O	O
/	SYM	O	O
kg	X	O	O
sc	NOUN	O	O
,	PUNCT	O	O
were	VERB	O	O
administered	VERB	O	O
to	ADP	O	O
adult	NOUN	O	O
White	PROPN	O	O
Leghorn	PROPN	O	O
chickens	VERB	O	O
24	NUM	O	O
hr	NOUN	O	O
after	ADP	O	O
they	PRON	O	O
were	VERB	O	O
placed	VERB	O	O
on	ADP	O	O
diets	NOUN	O	O
containing	VERB	O	O
0	NUM	O	O
to	ADP	O	O
300	NUM	O	O
ppm	NOUN	O	O
corticosterone	NOUN	O	I-Entity
.	PUNCT	O	O

Degenerating	VERB	O	B-Entity
myelinated	VERB	O	I-Entity
fibers	NOUN	O	I-Entity
were	VERB	O	O
also	ADV	O	O
evident	ADJ	O	O
in	ADP	O	O
distal	ADJ	O	O
levels	NOUN	O	O
of	ADP	O	O
the	DET	O	O
peripheral	ADJ	O	O
nerves	NOUN	O	O
of	ADP	O	O
chickens	NOUN	O	O
given	VERB	O	O
TOTP	PROPN	O	I-Entity
or	CCONJ	O	O
DFP	PROPN	O	I-Entity
.	PUNCT	O	O

-DOCSTART- (20973483)

An	DET	O	O
extremely	ADV	O	O
rare	ADJ	O	O
case	NOUN	O	O
of	ADP	O	O
delusional	ADJ	O	B-Entity
parasitosis	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
chronic	ADJ	O	B-Entity
hepatitis	NOUN	O	I-Entity
C	NOUN	O	I-Entity
patient	NOUN	O	O
during	ADP	O	O
pegylated	ADJ	O	B-Entity
interferon	NOUN	O	I-Entity
alpha-2b	X	O	I-Entity
and	CCONJ	O	O
ribavirin	VERB	O	I-Entity
treatment	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
patient	NOUN	O	O
had	VERB	O	O
a	DET	O	O
fever	NOUN	O	I-Entity
(	PUNCT	O	O
38.2	NUM	O	O
degrees	NOUN	O	O
C	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
fluctuating	VERB	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
(	PUNCT	O	O
between	ADP	O	O
165/90	NUM	O	O
and	CCONJ	O	O
130/70	NUM	O	O
mg	NUM	O	O
mm	PROPN	O	O
Hg	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
severe	ADJ	O	O
extrapyramidal	NOUN	O	B-Entity
symptoms	NOUN	O	I-Entity
.	PUNCT	O	O

Laboratory	ADJ	O	O
tests	NOUN	O	O
showed	VERB	O	O
an	DET	O	O
elevation	NOUN	O	O
of	ADP	O	O
creatine	NOUN	O	I-Entity
phosphokinase	NOUN	O	O
(	PUNCT	O	O
2218	NUM	O	O
IU	PROPN	O	O
/	SYM	O	O
L	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
aspartate	NOUN	O	I-Entity
aminotransferase	NOUN	O	O
(	PUNCT	O	O
134	NUM	O	O
IU	PROPN	O	O
/	SYM	O	O
L	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
alanine	NOUN	O	I-Entity
aminotransferase	NOUN	O	O
(	PUNCT	O	O
78	NUM	O	O
IU	PROPN	O	O
/	SYM	O	O
L	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
BUN	PROPN	O	O
(	PUNCT	O	O
27.9	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
ml	NOUN	O	O
)	PUNCT	O	O
levels	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
patient	NOUN	O	O
presented	VERB	O	O
with	ADP	O	O
symptoms	NOUN	O	O
of	ADP	O	O
neuroleptic	ADJ	O	B-Entity
malignant	NOUN	O	I-Entity
syndrome	NOUN	O	I-Entity
(	PUNCT	O	O
NMS	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
thus	ADV	O	O
demonstrating	VERB	O	O
that	ADP	O	O
NMS	PROPN	O	I-Entity
-	PUNCT	O	O
like	ADJ	O	O
symptoms	NOUN	O	O
can	VERB	O	O
occur	VERB	O	O
after	ADP	O	O
combined	VERB	O	O
paroxetine	NOUN	O	I-Entity
and	CCONJ	O	O
alprazolam	NOUN	O	I-Entity
treatment	NOUN	O	O
.	PUNCT	O	O

Children	NOUN	O	O
who	NOUN	O	O
have	VERB	O	O
status	NOUN	O	B-Entity
epilepticus	NOUN	O	I-Entity
have	VERB	O	O
continuous	ADJ	O	O
or	CCONJ	O	O
rapidly	ADV	O	O
repeating	VERB	O	O
seizures	NOUN	O	I-Entity
that	ADJ	O	O
may	VERB	O	O
be	VERB	O	O
life	NOUN	O	O
-	PUNCT	O	O
threatening	VERB	O	O
and	CCONJ	O	O
may	VERB	O	O
cause	VERB	O	O
life	NOUN	O	O
-	PUNCT	O	O
long	ADJ	O	O
changes	NOUN	O	O
in	ADP	O	O
brain	NOUN	O	O
and	CCONJ	O	O
behavior	NOUN	O	O
.	PUNCT	O	O

Male	PROPN	O	O
Sprague	PROPN	O	O
-	PUNCT	O	O
Dawley	PROPN	O	O
rats	NOUN	O	O
were	VERB	O	O
injected	VERB	O	O
with	ADP	O	O
saline	NOUN	O	O
on	ADP	O	O
postnatal	ADJ	O	O
day	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
)	PUNCT	O	O
20	NUM	O	O
,	PUNCT	O	O
or	CCONJ	O	O
a	DET	O	O
convulsant	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
pilocarpine	NOUN	O	I-Entity
on	ADP	O	O
P20	PROPN	O	O
or	CCONJ	O	O
P45	PROPN	O	O
.	PUNCT	O	O

This	DET	O	O
impairment	NOUN	O	O
may	VERB	O	O
explain	VERB	O	O
one	NUM	O	O
cause	NOUN	O	O
of	ADP	O	O
impaired	ADJ	O	B-Entity
auditory	ADJ	O	I-Entity
location	NOUN	O	I-Entity
discrimination	NOUN	O	I-Entity
in	ADP	O	O
humans	NOUN	O	O
.	PUNCT	O	O

There	ADV	O	O
were	VERB	O	O
3379	NUM	O	O
patients	NOUN	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	ADP	O	O
enalapril	VERB	O	I-Entity
with	ADP	O	O
a	DET	O	O
median	ADJ	O	O
follow	NOUN	O	O
-	PUNCT	O	O
up	NOUN	O	O
of	ADP	O	O
974	NUM	O	O
days	NOUN	O	O
and	CCONJ	O	O
3379	NUM	O	O
patients	NOUN	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	ADP	O	O
placebo	NOUN	O	O
with	ADP	O	O
a	DET	O	O
mean	ADJ	O	O
follow	NOUN	O	O
-	PUNCT	O	O
up	NOUN	O	O
of	ADP	O	O
967	NUM	O	O
days	NOUN	O	O
.	PUNCT	O	O

Continuous	PROPN	O	O
subcutaneous	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
mesna	NOUN	O	I-Entity
to	PART	O	O
prevent	VERB	O	O
ifosfamide	ADV	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hemorrhagic	ADJ	O	B-Entity
cystitis	NOUN	O	I-Entity
.	PUNCT	O	O

Hemorrhagic	ADJ	O	B-Entity
cystitis	NOUN	O	I-Entity
is	VERB	O	O
a	DET	O	O
major	ADJ	O	O
potential	ADJ	O	O
toxicity	NOUN	O	I-Entity
of	ADP	O	O
ifosfamide	NOUN	O	I-Entity
that	ADJ	O	O
can	VERB	O	O
be	VERB	O	O
prevented	VERB	O	O
by	ADP	O	O
administering	VERB	O	O
mesna	NOUN	O	I-Entity
along	ADP	O	O
with	ADP	O	O
the	DET	O	O
cytotoxic	ADJ	O	O
agent	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
suggested	VERB	O	O
that	ADP	O	O
ammonia	NOUN	O	I-Entity
blocks	NOUN	O	O
calcium	NOUN	O	I-Entity
channels	NOUN	O	O
.	PUNCT	O	O

Risk	NOUN	O	O
of	ADP	O	O
nephropathy	ADJ	O	I-Entity
after	ADP	O	O
consumption	NOUN	O	O
of	ADP	O	O
nonionic	ADJ	O	O
contrast	NOUN	O	B-Entity
media	NOUN	O	I-Entity
by	ADP	O	O
children	NOUN	O	O
undergoing	VERB	O	O
cardiac	ADJ	O	O
angiography	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
prospective	ADJ	O	O
study	NOUN	O	O
.	PUNCT	O	O

Despite	ADP	O	O
increasing	VERB	O	O
reports	NOUN	O	O
on	ADP	O	O
nonionic	ADJ	O	O
contrast	NOUN	O	B-Entity
media	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
nephropathy	NOUN	O	I-Entity
(	PUNCT	O	O
CIN	PROPN	O	I-Entity
)	PUNCT	O	O
in	ADP	O	O
hospitalized	VERB	O	O
adult	NOUN	O	O
patients	NOUN	O	O
during	ADP	O	O
cardiac	ADJ	O	O
procedures	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
studies	NOUN	O	O
in	ADP	O	O
pediatrics	NOUN	O	O
are	VERB	O	O
limited	ADJ	O	O
,	PUNCT	O	O
with	ADP	O	O
even	ADV	O	O
less	ADJ	O	O
focus	NOUN	O	O
on	ADP	O	O
possible	ADJ	O	O
predisposing	NOUN	O	O
factors	NOUN	O	O
and	CCONJ	O	O
preventive	ADJ	O	O
measures	NOUN	O	O
for	ADP	O	O
patients	NOUN	O	O
undergoing	VERB	O	O
cardiac	ADJ	O	O
angiography	NOUN	O	O
.	PUNCT	O	O

Risk	NOUN	O	O
of	ADP	O	O
renal	ADJ	O	B-Entity
failure	NOUN	O	I-Entity
,	PUNCT	O	O
Injury	PROPN	O	B-Entity
to	ADP	O	I-Entity
the	DET	O	I-Entity
kidney	NOUN	O	I-Entity
,	PUNCT	O	O
Failure	NOUN	O	B-Entity
of	ADP	O	I-Entity
kidney	NOUN	O	I-Entity
function	NOUN	O	I-Entity
,	PUNCT	O	O
Loss	PROPN	O	B-Entity
of	ADP	O	I-Entity
kidney	NOUN	O	I-Entity
function	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
End	PROPN	O	O
-	PUNCT	O	O
stage	NOUN	O	O
renal	ADJ	O	B-Entity
damage	NOUN	O	I-Entity
(	PUNCT	O	O
RIFLE	PROPN	O	O
criteria	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
used	VERB	O	O
to	PART	O	O
define	VERB	O	O
CIN	PROPN	O	I-Entity
and	CCONJ	O	O
its	ADJ	O	O
incidence	NOUN	O	O
in	ADP	O	O
the	DET	O	O
study	NOUN	O	O
population	NOUN	O	O
.	PUNCT	O	O

Although	ADP	O	O
clinically	ADV	O	O
silent	ADJ	O	O
,	PUNCT	O	O
CIN	PROPN	O	I-Entity
is	VERB	O	O
not	ADV	O	O
rare	ADJ	O	O
in	ADP	O	O
pediatrics	NOUN	O	O
.	PUNCT	O	O

-DOCSTART- (7189975)

In	ADP	O	O
a	DET	O	O
more	ADV	O	O
complex	ADJ	O	O
task	NOUN	O	O
commonly	ADV	O	O
used	VERB	O	O
to	PART	O	O
evaluate	VERB	O	O
major	ADJ	O	O
akinetic	ADJ	O	I-Entity
symptoms	NOUN	O	O
of	ADP	O	O
PD	PROPN	O	I-Entity
patients	NOUN	O	O
,	PUNCT	O	O
5	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	X	O	O
AMN082	PROPN	O	I-Entity
reverses	VERB	O	O
the	DET	O	O
increased	VERB	O	O
reaction	NOUN	O	O
time	NOUN	O	O
to	PART	O	O
respond	VERB	O	O
to	ADP	O	O
a	DET	O	O
cue	NOUN	O	O
of	ADP	O	O
bilateral	ADJ	O	O
6-OHDA	NUM	O	I-Entity
-	PUNCT	O	O
lesioned	VERB	O	O
rats	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
observed	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
NIMO	PROPN	O	I-Entity
may	VERB	O	O
have	VERB	O	O
been	VERB	O	O
attributable	ADJ	O	O
to	ADP	O	O
the	DET	O	O
preservation	NOUN	O	O
of	ADP	O	O
calcium	NOUN	O	I-Entity
homeostasis	NOUN	O	O
during	ADP	O	O
hypotension	NOUN	O	I-Entity
,	PUNCT	O	O
because	ADP	O	O
there	ADV	O	O
were	VERB	O	O
no	DET	O	O
differences	NOUN	O	O
in	ADP	O	O
the	DET	O	O
PbtO(2	PROPN	O	O
)	PUNCT	O	O
indices	NOUN	O	O
among	ADP	O	O
groups	NOUN	O	O
.	PUNCT	O	O


In	ADP	O	O
the	DET	O	O
present	ADJ	O	O
case	NOUN	O	O
,	PUNCT	O	O
complete	ADJ	O	O
atrioventricular	NOUN	O	B-Entity
(	PUNCT	O	I-Entity
AV	PROPN	O	I-Entity
)	PUNCT	O	I-Entity
block	NOUN	O	I-Entity
with	ADP	O	O
syncopal	ADJ	O	B-Entity
attacks	NOUN	O	I-Entity
developed	VERB	O	O
secondary	ADJ	O	O
to	ADP	O	O
lithium	NOUN	O	I-Entity
therapy	NOUN	O	O
,	PUNCT	O	O
necessitating	VERB	O	O
permanent	ADJ	O	O
pacemaker	NOUN	O	O
implantation	NOUN	O	O
.	PUNCT	O	O

Activities	NOUN	O	O
of	ADP	O	O
heart	NOUN	O	O
tissue	NOUN	O	O
enzymic	NOUN	O	O
antioxidants	NOUN	O	O
and	CCONJ	O	O
serum	NOUN	O	O
non	NOUN	O	O
-	PUNCT	O	O
enzymic	NOUN	O	O
antioxidants	NOUN	O	O
levels	NOUN	O	O
rose	VERB	O	O
significantly	ADV	O	O
upon	ADP	O	O
mangiferin	ADJ	O	I-Entity
administration	NOUN	O	O
as	ADP	O	O
compared	VERB	O	O
to	ADP	O	O
ISPH	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
MI	PROPN	O	I-Entity
rats	NOUN	O	O
.	PUNCT	O	O

-DOCSTART- (16563323)

Injections	NOUN	O	O
of	ADP	O	O
scopolamine	NOUN	O	I-Entity
into	ADP	O	O
mice	NOUN	O	O
resulted	VERB	O	O
in	ADP	O	O
impaired	ADJ	O	O
performance	NOUN	O	O
on	ADP	O	O
Y	PROPN	O	O
-	PUNCT	O	O
maze	NOUN	O	O
tests	NOUN	O	O
(	PUNCT	O	O
a	DET	O	O
37%	NUM	O	O
decreases	NOUN	O	O
in	ADP	O	O
alternation	NOUN	O	O
behavior	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

No	DET	O	O
organic	ADJ	O	O
cause	NOUN	O	O
of	ADP	O	O
hiccups	NOUN	O	I-Entity
was	VERB	O	O
identified	VERB	O	O
despite	ADP	O	O
extensive	ADJ	O	O
investigation	NOUN	O	O
.	PUNCT	O	O

Diagnosis	PROPN	O	O
of	ADP	O	O
drug	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
hiccups	NOUN	O	I-Entity
is	VERB	O	O
difficult	ADJ	O	O
and	CCONJ	O	O
often	ADV	O	O
achieved	VERB	O	O
only	ADV	O	O
by	ADP	O	O
a	DET	O	O
process	NOUN	O	O
of	ADP	O	O
elimination	NOUN	O	O
.	PUNCT	O	O

There	ADV	O	O
were	VERB	O	O
347	NUM	O	O
confirmed	VERB	O	O
stroke	NOUN	O	I-Entity
cases	NOUN	O	O
and	CCONJ	O	O
1,021	NUM	O	O
controls	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
rates	NOUN	O	O
of	ADP	O	O
onset	NOUN	O	O
of	ADP	O	O
the	DET	O	O
action	NOUN	O	O
of	ADP	O	O
cimetidine	NOUN	O	I-Entity
and	CCONJ	O	O
ranitidine	NOUN	O	I-Entity
were	VERB	O	O
the	DET	O	O
same	ADJ	O	O
.	PUNCT	O	O

-DOCSTART- (3670965)

Pathologic	ADJ	O	O
confirmation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
diagnosis	NOUN	O	O
of	ADP	O	O
Reye	PROPN	O	B-Entity
syndrome	NOUN	O	I-Entity
was	VERB	O	O
accomplished	VERB	O	O
in	ADP	O	O
90%	NUM	O	O
of	ADP	O	O
the	DET	O	O
cases	NOUN	O	O
.	PUNCT	O	O

Previous	ADJ	O	O
experiments	NOUN	O	O
in	ADP	O	O
this	DET	O	O
laboratory	NOUN	O	O
have	VERB	O	O
shown	VERB	O	O
that	ADP	O	O
microinjection	NOUN	O	O
of	ADP	O	O
methyldopa	NOUN	O	I-Entity
onto	ADP	O	O
the	DET	O	O
ventrolateral	ADJ	O	O
cells	NOUN	O	O
of	ADP	O	O
the	DET	O	O
B3	PROPN	O	O
serotonin	NOUN	O	I-Entity
neurons	NOUN	O	O
in	ADP	O	O
the	DET	O	O
medulla	NOUN	O	O
elicits	VERB	O	O
a	DET	O	O
hypotensive	ADJ	O	I-Entity
response	NOUN	O	O
mediated	VERB	O	O
by	ADP	O	O
a	DET	O	O
projection	NOUN	O	O
descending	VERB	O	O
into	ADP	O	O
the	DET	O	O
spinal	ADJ	O	O
cord	NOUN	O	O
.	PUNCT	O	O

Future	NOUN	O	O
controlled	VERB	O	O
studies	NOUN	O	O
are	VERB	O	O
needed	VERB	O	O
to	PART	O	O
further	ADV	O	O
investigate	VERB	O	O
the	DET	O	O
effectiveness	NOUN	O	O
and	CCONJ	O	O
safety	NOUN	O	O
of	ADP	O	O
yohimbine	NOUN	O	I-Entity
for	ADP	O	O
this	DET	O	O
indication	NOUN	O	O
.	PUNCT	O	O

Thus	ADV	O	O
,	PUNCT	O	O
we	PRON	O	O
conclude	VERB	O	O
that	ADP	O	O
tacrolimus	NOUN	O	I-Entity
induces	VERB	O	O
reversible	ADJ	O	O
myocardial	ADJ	O	B-Entity
hypertrophy	NOUN	O	I-Entity
.	PUNCT	O	O

Attenuated	ADJ	O	O
disruption	NOUN	O	O
of	ADP	O	O
prepulse	NOUN	O	O
inhibition	NOUN	O	O
by	ADP	O	O
dopaminergic	ADJ	O	O
stimulation	NOUN	O	O
after	ADP	O	O
maternal	ADJ	O	O
deprivation	NOUN	O	O
and	CCONJ	O	O
adolescent	ADJ	O	O
corticosterone	NOUN	O	I-Entity
treatment	NOUN	O	O
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
investigated	VERB	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
an	DET	O	O
early	ADJ	O	O
stress	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
form	NOUN	O	O
of	ADP	O	O
maternal	ADJ	O	O
deprivation	NOUN	O	O
,	PUNCT	O	O
combined	VERB	O	O
with	ADP	O	O
a	DET	O	O
later	ADJ	O	O
stress	NOUN	O	O
,	PUNCT	O	O
simulated	VERB	O	O
by	ADP	O	O
chronic	ADJ	O	O
periadolescent	NOUN	O	O
corticosterone	NOUN	O	I-Entity
treatment	NOUN	O	O
,	PUNCT	O	O
on	ADP	O	O
behaviour	NOUN	O	O
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

To	PART	O	O
demonstrate	VERB	O	O
the	DET	O	O
relationship	NOUN	O	O
between	ADP	O	O
peripheral	ADJ	O	O
iron	NOUN	O	I-Entity
overload	NOUN	O	O
and	CCONJ	O	O
dopaminergic	ADJ	O	O
neuron	NOUN	O	O
loss	NOUN	O	O
in	ADP	O	O
rat	NOUN	O	O
substantia	NOUN	O	O
nigra	NOUN	O	O
(	PUNCT	O	O
SN	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
we	PRON	O	O
used	VERB	O	O
fast	ADV	O	O
cyclic	ADJ	O	O
voltammetry	NOUN	O	O
,	PUNCT	O	O
tyrosine	NOUN	O	I-Entity
hydroxylase	NOUN	O	O
(	PUNCT	O	O
TH	PROPN	O	O
)	PUNCT	O	O

immunohistochemistry	NOUN	O	O
,	PUNCT	O	O
Perls	PROPN	O	O
'	PART	O	O
iron	NOUN	O	I-Entity
staining	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
high	ADJ	O	O
performance	NOUN	O	O
liquid	NOUN	O	O
chromatography	NOUN	O	O
-	PUNCT	O	O
electrochemical	ADJ	O	O
detection	NOUN	O	O
to	PART	O	O
study	VERB	O	O
the	DET	O	O
degeneration	NOUN	O	B-Entity
of	ADP	O	I-Entity
dopaminergic	ADJ	O	I-Entity
neurons	NOUN	O	I-Entity
and	CCONJ	O	O
increased	VERB	O	O
iron	NOUN	O	I-Entity
content	NOUN	O	O
in	ADP	O	O
the	DET	O	O
SN	PROPN	O	O
of	ADP	O	O
iron	NOUN	O	B-Entity
dextran	NOUN	O	I-Entity
overloaded	ADJ	O	O
animals	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
peripheral	ADJ	O	O
iron	NOUN	O	B-Entity
dextran	NOUN	O	I-Entity
can	VERB	O	O
increase	VERB	O	O
the	DET	O	O
iron	NOUN	O	I-Entity
level	NOUN	O	O
in	ADP	O	O
the	DET	O	O
SN	PROPN	O	O
,	PUNCT	O	O
where	ADV	O	O
excessive	ADJ	O	O
iron	NOUN	O	I-Entity
causes	VERB	O	O
the	DET	O	O
degeneration	NOUN	O	B-Entity
of	ADP	O	I-Entity
dopaminergic	ADJ	O	I-Entity
neurons	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
results	NOUN	O	O
of	ADP	O	O
skin	NOUN	O	B-Entity
lesion	NOUN	O	I-Entity
biopsies	NOUN	O	O
were	VERB	O	O
available	ADJ	O	O
in	ADP	O	O
3	NUM	O	O
patients	NOUN	O	O
,	PUNCT	O	O
confirming	VERB	O	O
LV	PROPN	O	B-Entity
Cutaneous	PROPN	O	I-Entity
lesions	NOUN	O	I-Entity
resolved	VERB	O	O
in	ADP	O	O
all	DET	O	O
patients	NOUN	O	O
after	ADP	O	O
warfarin	NOUN	O	I-Entity
was	VERB	O	O
discontinued	VERB	O	O
.	PUNCT	O	O

LV	NOUN	O	I-Entity
may	VERB	O	O
be	VERB	O	O
a	DET	O	O
late	ADJ	O	O
-	PUNCT	O	O
onset	NOUN	O	O
adverse	ADJ	O	O
reaction	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
warfarin	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
generated	VERB	O	O
beta2(-/-	NOUN	O	O
)	PUNCT	O	O
mice	NOUN	O	O
to	PART	O	O
investigate	VERB	O	O
the	DET	O	O
role	NOUN	O	O
of	ADP	O	O
beta2	NOUN	O	O
in	ADP	O	O
control	NOUN	O	O
of	ADP	O	O
sodium	NOUN	O	I-Entity
channel	NOUN	O	O
density	NOUN	O	O
,	PUNCT	O	O
localization	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
function	NOUN	O	O
in	ADP	O	O
neurons	NOUN	O	O
in	ADP	O	O
vivo	NOUN	O	O
.	PUNCT	O	O

Our	ADJ	O	O
observations	NOUN	O	O
show	VERB	O	O
that	ADP	O	O
beta2-subunits	NOUN	O	O
play	VERB	O	O
an	DET	O	O
important	ADJ	O	O
role	NOUN	O	O
in	ADP	O	O
the	DET	O	O
regulation	NOUN	O	O
of	ADP	O	O
sodium	NOUN	O	I-Entity
channel	NOUN	O	O
density	NOUN	O	O
and	CCONJ	O	O
function	NOUN	O	O
in	ADP	O	O
neurons	NOUN	O	O
in	ADP	O	O
vivo	NOUN	O	O
and	CCONJ	O	O
are	VERB	O	O
required	VERB	O	O
for	ADP	O	O
normal	ADJ	O	O
action	NOUN	O	O
potential	ADJ	O	O
generation	NOUN	O	O
and	CCONJ	O	O
control	NOUN	O	O
of	ADP	O	O
excitability	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
data	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
MM	PROPN	O	O
opioid	NOUN	O	O
abusers	NOUN	O	O
represent	VERB	O	O
a	DET	O	O
pain	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
intolerant	ADJ	O	I-Entity
subset	NOUN	O	O
of	ADP	O	O
clinical	ADJ	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Over	ADP	O	O
expression	NOUN	O	O
of	ADP	O	O
vascular	ADJ	O	O
endothelial	ADJ	O	O
growth	NOUN	O	O
factor	NOUN	O	O
and	CCONJ	O	O
its	ADJ	O	O
receptor	NOUN	O	O
during	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
estrogen	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
rat	NOUN	O	O
pituitary	NOUN	O	B-Entity
tumors	NOUN	O	I-Entity
may	VERB	O	O
mediate	VERB	O	O
estrogen	NOUN	O	I-Entity
-	PUNCT	O	O
initiated	VERB	O	O
tumor	NOUN	O	I-Entity
angiogenesis	NOUN	O	O
.	PUNCT	O	O

-DOCSTART- (2722224)

A	DET	O	O
shift	NOUN	O	O
to	ADP	O	O
the	DET	O	O
left	NOUN	O	O
in	ADP	O	O
the	DET	O	O
dose	NOUN	O	O
-	PUNCT	O	O
response	NOUN	O	O
relation	NOUN	O	O
and	CCONJ	O	O
fall	VERB	O	O
in	ADP	O	O
threshold	NOUN	O	O
suggested	VERB	O	O
increased	VERB	O	O
sensitivity	NOUN	O	O
to	ADP	O	O
norepinephrine	VERB	O	I-Entity
after	ADP	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
significant	ADJ	O	O
decrease	NOUN	O	O
in	ADP	O	O
the	DET	O	O
baseline	NOUN	O	O
excretion	NOUN	O	O
rate	NOUN	O	O
of	ADP	O	O
uric	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
was	VERB	O	O
found	VERB	O	O
in	ADP	O	O
rats	NOUN	O	O
given	VERB	O	O
suprofen	NOUN	O	I-Entity
,	PUNCT	O	O
compared	VERB	O	O
with	ADP	O	O
drug	NOUN	O	O
-	PUNCT	O	O
free	ADJ	O	O
controls	NOUN	O	O
.	PUNCT	O	O

Cocaine	NOUN	O	I-Entity
generated	VERB	O	O
more	ADV	O	O
abnormal	ADJ	O	O
behaviors	NOUN	O	O
in	ADP	O	O
the	DET	O	O
brainstem	NOUN	O	O
perturbation	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
especially	ADV	O	O
the	DET	O	O
electrically	ADV	O	O
perturbated	VERB	O	O
subjects	NOUN	O	O
.	PUNCT	O	O

-DOCSTART- (873132)

Furthermore	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
rat	NOUN	O	O
converts	VERB	O	O
deoxycholic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
poor	ADJ	O	O
choleretic	NOUN	O	O
,	PUNCT	O	O
to	ADP	O	O
taurocholic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
good	ADJ	O	O
choleretic	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
suggest	VERB	O	O
that	ADP	O	O
caution	NOUN	O	O
be	VERB	O	O
taken	VERB	O	O
when	ADV	O	O
cisapride	NOUN	O	I-Entity
is	VERB	O	O
prescribed	VERB	O	O
with	ADP	O	O
any	DET	O	O
potent	ADJ	O	O
inhibitor	NOUN	O	O
of	ADP	O	O
CYP3A4	PROPN	O	O
,	PUNCT	O	O
including	VERB	O	O
diltiazem	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
levels	NOUN	O	O
5	NUM	O	O
and	CCONJ	O	O
6	NUM	O	O
the	DET	O	O
carboplatin	NOUN	O	I-Entity
dose	NOUN	O	O
was	VERB	O	O
targeted	VERB	O	O
at	ADP	O	O
AUCs	PROPN	O	O
of	ADP	O	O
6	NUM	O	O
and	CCONJ	O	O
7.5	NUM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
combined	VERB	O	O
with	ADP	O	O
a	DET	O	O
fixed	VERB	O	O
paclitaxel	NOUN	O	I-Entity
dose	NOUN	O	O
of	ADP	O	O
185	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
m2	NOUN	O	O
.	PUNCT	O	O

Treatment	NOUN	O	O
of	ADP	O	O
tacrolimus	NOUN	O	I-Entity
-	PUNCT	O	O
related	VERB	O	O
adverse	ADJ	O	O
effects	NOUN	O	O
by	ADP	O	O
conversion	NOUN	O	O
to	ADP	O	O
cyclosporine	NOUN	O	I-Entity
in	ADP	O	O
liver	NOUN	O	O
transplant	NOUN	O	O
recipients	NOUN	O	O
.	PUNCT	O	O

Relative	ADJ	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
toxicity	NOUN	O	I-Entity
of	ADP	O	O
netilmicin	NOUN	O	I-Entity
and	CCONJ	O	O
tobramycin	NOUN	O	I-Entity
in	ADP	O	O
oncology	NOUN	O	O
patients	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
conclude	VERB	O	O
that	ADP	O	O
aminoglycoside	ADV	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
ototoxicity	NOUN	O	I-Entity
was	VERB	O	O
less	ADV	O	O
severe	ADJ	O	O
and	CCONJ	O	O
more	ADV	O	O
often	ADV	O	O
reversible	ADJ	O	O
with	ADP	O	O
netilmicin	NOUN	O	I-Entity
than	ADP	O	O
with	ADP	O	O
tobramycin	NOUN	O	I-Entity
.	PUNCT	O	O

Ibuprofen	PROPN	O	I-Entity
,	PUNCT	O	O
sulindac	NOUN	O	I-Entity
,	PUNCT	O	O
mefenamic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
low	ADJ	O	O
dose	NOUN	O	O
meclofenamic	NOUN	O	B-Entity
acid	NOUN	O	I-Entity
increased	VERB	O	O
the	DET	O	O
latency	NOUN	O	O
-	PUNCT	O	O
to	ADP	O	O
-	PUNCT	O	O
onset	NOUN	O	O
in	ADP	O	O
the	DET	O	O
flurothyl	NOUN	O	I-Entity
and/or	CCONJ	O	O
PTZ	NOUN	O	I-Entity
models	NOUN	O	O
;	PUNCT	O	O
the	DET	O	O
electroshock	NOUN	O	O
,	PUNCT	O	O
picrotoxin	NOUN	O	I-Entity
and	CCONJ	O	O
bicuculline	NOUN	O	I-Entity
models	NOUN	O	O
were	VERB	O	O
not	ADV	O	O
significantly	ADV	O	O
affected	VERB	O	O
by	ADP	O	O
any	DET	O	O
of	ADP	O	O
the	DET	O	O
pretreatment	NOUN	O	O
agents	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
PGs	NOUN	O	I-Entity
are	VERB	O	O
involved	VERB	O	O
in	ADP	O	O
the	DET	O	O
mechanism(s	PROPN	O	O
)	PUNCT	O	O
underlying	VERB	O	O
fluorthyl-	NOUN	O	I-Entity
and	CCONJ	O	O
PTZ	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
convulsions	NOUN	O	I-Entity
,	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
picrotoxin-	ADJ	O	I-Entity
,	PUNCT	O	O
electroshock-	ADJ	O	O
,	PUNCT	O	O
or	CCONJ	O	O
bicuculline	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
convulsions	NOUN	O	I-Entity
.	PUNCT	O	O

Methamphetamine	NOUN	O	I-Entity
or	CCONJ	O	O
amphetamine	NOUN	O	I-Entity
levels	NOUN	O	O
were	VERB	O	O
related	VERB	O	O
to	ADP	O	O
several	ADJ	O	O
psychopathology	NOUN	O	O
scores	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
global	ADJ	O	O
hyperkinesia	NOUN	O	I-Entity
rating	NOUN	O	O
.	PUNCT	O	O

-DOCSTART- (6699841)

The	DET	O	O
most	ADV	O	O
common	ADJ	O	O
adverse	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
intravenous	ADJ	O	O
ribavirin	NOUN	O	I-Entity
is	VERB	O	O
reversible	ADJ	O	O
mild	ADJ	O	O
anemia	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
availability	NOUN	O	O
of	ADP	O	O
newer	NOUN	O	O
rapid	ADJ	O	O
diagnostic	ADJ	O	O
techniques	NOUN	O	O
,	PUNCT	O	O
such	ADJ	O	O
as	ADP	O	O
polymerase	NOUN	O	O
chain	NOUN	O	O
reaction	NOUN	O	O
,	PUNCT	O	O
may	VERB	O	O
make	VERB	O	O
earlier	ADJ	O	O
,	PUNCT	O	O
more	ADV	O	O
effective	ADJ	O	O
treatment	NOUN	O	O
of	ADP	O	O
adenovirus	NOUN	O	B-Entity
infection	NOUN	O	I-Entity
possible	ADJ	O	O
.	PUNCT	O	O

Catalepsy	PROPN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
combinations	NOUN	O	O
of	ADP	O	O
ketamine	NOUN	O	I-Entity
and	CCONJ	O	O
morphine	NOUN	O	I-Entity
:	PUNCT	O	O
potentiation	NOUN	O	O
,	PUNCT	O	O
antagonism	NOUN	O	O
,	PUNCT	O	O
tolerance	NOUN	O	O
and	CCONJ	O	O
cross	VERB	O	O
-	PUNCT	O	O
tolerance	NOUN	O	O
in	ADP	O	O
the	DET	O	O
rat	NOUN	O	O
.	PUNCT	O	O

Previous	ADJ	O	O
studies	NOUN	O	O
demonstrated	VERB	O	O
that	ADP	O	O
both	DET	O	O
ketamine	NOUN	O	I-Entity
and	CCONJ	O	O
morphine	NOUN	O	I-Entity
induced	VERB	O	O
analgesia	NOUN	O	I-Entity
and	CCONJ	O	O
catalepsy	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
rat	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
identified	VERB	O	O
27	NUM	O	O
reports	NOUN	O	O
of	ADP	O	O
toxic	ADJ	O	O
leukoencephalopathy	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
methotrexate	NOUN	O	I-Entity
(	PUNCT	O	O
intrathecal	ADJ	O	O
,	PUNCT	O	O
systemic	ADJ	O	O
)	PUNCT	O	O
,	PUNCT	O	O
5-fluorouracil	NUM	O	I-Entity
and	CCONJ	O	O
its	ADJ	O	O
derivative	ADJ	O	O
carmofur	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
capecitabine	NOUN	O	I-Entity
.	PUNCT	O	O

Inhibition	NOUN	O	O
of	ADP	O	O
Na(+	PROPN	O	I-Entity
)	PUNCT	O	O
channels	NOUN	O	O
by	ADP	O	O
local	ADJ	O	O
anesthetics	NOUN	O	O
may	VERB	O	O
regulate	VERB	O	O
desipramine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
down	ADV	O	O
-	PUNCT	O	O
regulation	NOUN	O	O
of	ADP	O	O
NET	PROPN	O	O
function	NOUN	O	O
.	PUNCT	O	O

Repeated	VERB	O	O
administration	NOUN	O	O
of	ADP	O	O
cocaine	NOUN	O	I-Entity
induces	VERB	O	O
up	ADP	O	O
-	PUNCT	O	O
regulation	NOUN	O	O
of	ADP	O	O
hippocampal	ADJ	O	O
NET	PROPN	O	O
function	NOUN	O	O
.	PUNCT	O	O

Desipramine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
sensitization	NOUN	O	O
of	ADP	O	O
lidocaine	NOUN	O	I-Entity
seizures	NOUN	O	I-Entity
may	VERB	O	O
have	VERB	O	O
a	DET	O	O
mechanism	NOUN	O	O
distinct	ADV	O	O
from	ADP	O	O
kindling	VERB	O	O
resulting	VERB	O	O
from	ADP	O	O
repeated	VERB	O	O
administration	NOUN	O	O
of	ADP	O	O
cocaine	NOUN	O	I-Entity
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
:	PUNCT	O	O
To	PART	O	O
describe	VERB	O	O
3	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
calcium	NOUN	O	B-Entity
carbonate	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hypercalcemia	NOUN	O	I-Entity
and	CCONJ	O	O
gain	VERB	O	O
insights	NOUN	O	O
into	ADP	O	O
the	DET	O	O
cause	NOUN	O	O
and	CCONJ	O	O
management	NOUN	O	O
of	ADP	O	O
the	DET	O	O
milk	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
alkali	NOUN	O	I-Entity
syndrome	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
2	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
the	DET	O	O
higher	ADJ	O	O
serum	NOUN	O	O
calcium	NOUN	O	I-Entity
concentrations	NOUN	O	O
received	VERB	O	O
pamidronate	NOUN	O	I-Entity
intravenously	ADV	O	O
(	PUNCT	O	O
60	NUM	O	O
and	CCONJ	O	O
30	NUM	O	O
mg	NUM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
)	PUNCT	O	O
,	PUNCT	O	O
which	ADJ	O	O
caused	VERB	O	O
severe	ADJ	O	O
hypocalcemia	NOUN	O	I-Entity
.	PUNCT	O	O

Furthermore	ADV	O	O
,	PUNCT	O	O
dopamine	NOUN	O	I-Entity
appeared	VERB	O	O
to	PART	O	O
act	VERB	O	O
on	ADP	O	O
systems	NOUN	O	O
more	ADV	O	O
closely	ADV	O	O
involved	VERB	O	O
with	ADP	O	O
the	DET	O	O
induction	NOUN	O	O
of	ADP	O	O
ketamine	NOUN	O	I-Entity
catatonia	NOUN	O	I-Entity
rather	ADV	O	O
than	ADP	O	O
directly	ADV	O	O
on	ADP	O	O
the	DET	O	O
pituitary	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (7910951)


Thiazide	PROPN	O	I-Entity
diuretics	NOUN	O	O
,	PUNCT	O	O
hypokalemia	NOUN	O	I-Entity
and	CCONJ	O	O
cardiac	ADJ	O	B-Entity
arrhythmias	NOUN	O	I-Entity
.	PUNCT	O	O

After	ADP	O	O
stopping	VERB	O	O
the	DET	O	O
beta	NOUN	O	O
-	PUNCT	O	O
agonist	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
after	ADP	O	O
a	DET	O	O
week	NOUN	O	O
with	ADP	O	O
the	DET	O	O
atenolol	NOUN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
arrhythmia	NOUN	O	I-Entity
disappeared	VERB	O	O
.	PUNCT	O	O

In	ADP	O	O
contrast	NOUN	O	O
,	PUNCT	O	O
AZT	PROPN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
FasL	PROPN	O	O
Tg	PROPN	O	O
mice	NOUN	O	O
developed	VERB	O	O
cardiac	ADJ	O	B-Entity
dilation	NOUN	O	I-Entity
and	CCONJ	O	O
depressed	ADJ	O	O
cardiac	ADJ	O	O
function	NOUN	O	O
in	ADP	O	O
a	DET	O	O
dose	NOUN	O	O
-	PUNCT	O	O
dependent	ADJ	O	O
manner	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
concomitant	ADJ	O	O
inflammatory	ADJ	O	O
infiltration	NOUN	O	O
of	ADP	O	O
both	DET	O	O
ventricles	NOUN	O	O
.	PUNCT	O	O


With	ADP	O	O
this	DET	O	O
model	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
were	VERB	O	O
able	ADJ	O	O
to	PART	O	O
identify	VERB	O	O
diffuse	NOUN	O	O
cortical	ADJ	O	O
hypoxia	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
puromycin	NOUN	O	B-Entity
aminonucleoside	ADV	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
nephrotic	ADJ	O	B-Entity
syndrome	NOUN	O	I-Entity
and	CCONJ	O	O
focal	ADJ	O	O
and	CCONJ	O	O
segmental	ADJ	O	O
hypoxia	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
remnant	ADJ	O	O
kidney	NOUN	O	O
model	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
was	VERB	O	O
designed	VERB	O	O
to	PART	O	O
assess	VERB	O	O
the	DET	O	O
ability	NOUN	O	O
of	ADP	O	O
spironolactone	NOUN	O	I-Entity
to	PART	O	O
reduce	VERB	O	O
potassium	NOUN	O	I-Entity
requirements	NOUN	O	O
and	CCONJ	O	O
to	PART	O	O
prevent	VERB	O	O
hypokalemia	NOUN	O	I-Entity
in	ADP	O	O
neutropenic	ADJ	O	I-Entity
patients	NOUN	O	O
on	ADP	O	O
AmB	PROPN	O	I-Entity
treatment	NOUN	O	O
.	PUNCT	O	O


Twenty	NUM	O	O
renal	ADJ	O	O
transplant	NOUN	O	O
recipients	NOUN	O	O
were	VERB	O	O
switched	VERB	O	O
to	ADP	O	O
fixed	VERB	O	O
dose	NOUN	O	O
rapamycin	NOUN	O	I-Entity
(	PUNCT	O	O
RAPA	PROPN	O	I-Entity
)	PUNCT	O	O
(	PUNCT	O	O
5	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
day	NOUN	O	O
)	PUNCT	O	O
0	NUM	O	O
to	ADP	O	O
204	NUM	O	O
months	NOUN	O	O
posttransplant	ADJ	O	O
.	PUNCT	O	O

Five	NUM	O	O
patients	NOUN	O	O
developed	VERB	O	O
pneumonia	NOUN	O	I-Entity
(	PUNCT	O	O
two	NUM	O	O
Pneumocystis	PROPN	O	B-Entity
carinii	NOUN	O	I-Entity
pneumonia	NOUN	O	I-Entity
,	PUNCT	O	O
one	NUM	O	O
infectious	ADJ	O	B-Entity
mononucleosis	NOUN	O	I-Entity
with	ADP	O	O
polyclonal	ADJ	O	O
PTLD	PROPN	O	I-Entity
lung	NOUN	O	O
infiltrate	VERB	O	O
)	PUNCT	O	O
and	CCONJ	O	O
two	NUM	O	O
had	VERB	O	O
bronchiolitis	NOUN	O	B-Entity
obliterans	NOUN	O	I-Entity
.	PUNCT	O	O

Structural	PROPN	O	B-Entity
and	CCONJ	O	I-Entity
functional	ADJ	O	I-Entity
impairment	NOUN	O	I-Entity
of	ADP	O	I-Entity
mitochondria	NOUN	O	I-Entity
in	ADP	O	O
adriamycin	ADV	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cardiomyopathy	NOUN	O	I-Entity
in	ADP	O	O
mice	NOUN	O	O
:	PUNCT	O	O
suppression	NOUN	O	O
of	ADP	O	O
cytochrome	NOUN	O	O
c	NOUN	O	O
oxidase	NOUN	O	O
II	PROPN	O	O
gene	NOUN	O	O
expression	NOUN	O	O
.	PUNCT	O	O

Of	ADP	O	O
60	NUM	O	O
epileptic	ADJ	O	I-Entity
women	NOUN	O	O
with	ADP	O	O
periconceptional	ADJ	O	O
folic	NOUN	O	B-Entity
acid	NOUN	O	I-Entity
(	PUNCT	O	O
0.8	NUM	O	O
mg)-containing	VERB	O	O
multivitamin	NOUN	O	O
supplementation	NOUN	O	O
,	PUNCT	O	O
no	DET	O	O
one	NOUN	O	O
developed	VERB	O	O
epilepsy	NOUN	O	I-Entity
-	PUNCT	O	O
related	VERB	O	O
side	NOUN	O	O
effects	NOUN	O	O
during	ADP	O	O
the	DET	O	O
periconception	NOUN	O	O
period	NOUN	O	O
.	PUNCT	O	O


Our	ADJ	O	O
aim	NOUN	O	O
was	VERB	O	O
to	PART	O	O
assess	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
treatment	NOUN	O	O
with	ADP	O	O
a	DET	O	O
prokinetic	ADJ	O	O
agent	NOUN	O	O
,	PUNCT	O	O
cisapride	NOUN	O	I-Entity
,	PUNCT	O	O
on	ADP	O	O
postprandial	ADJ	O	O
jejunal	ADJ	O	O
motility	NOUN	O	O
and	CCONJ	O	O
symptoms	NOUN	O	O
in	ADP	O	O
the	DET	O	O
irritable	ADJ	O	B-Entity
bowel	NOUN	O	I-Entity
syndrome	NOUN	O	I-Entity
(	PUNCT	O	O
IBS	PROPN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
a	DET	O	O
case	NOUN	O	O
of	ADP	O	O
ventricular	ADJ	O	B-Entity
dysrhythmias	NOUN	O	I-Entity
that	ADJ	O	O
occurred	VERB	O	O
after	ADP	O	O
six	NUM	O	O
therapeutic	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
clarithromycin	NOUN	O	I-Entity
.	PUNCT	O	O

-DOCSTART- (8514073)

GYKI-41	SYM	O	B-Entity
900	NUM	O	I-Entity
has	VERB	O	O
a	DET	O	O
negligible	ADJ	O	O
cardiodepressant	NOUN	O	O
activity	NOUN	O	O
;	PUNCT	O	O
it	PRON	O	O
is	VERB	O	O
not	ADV	O	O
cardioselective	ADJ	O	O
.	PUNCT	O	O


These	DET	O	O
results	NOUN	O	O
provide	VERB	O	O
a	DET	O	O
reasonable	ADJ	O	O
explanation	NOUN	O	O
for	ADP	O	O
the	DET	O	O
beneficial	ADJ	O	O
effects	NOUN	O	O
observed	VERB	O	O
in	ADP	O	O
some	DET	O	O
encephalopathic	ADJ	O	I-Entity
patients	NOUN	O	O
receiving	VERB	O	O
L	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
dopa	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
heparin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
platelet	NOUN	O	B-Entity
aggregation	NOUN	O	I-Entity
test	NOUN	O	O
was	VERB	O	O
negative	ADJ	O	O
in	ADP	O	O
these	DET	O	O
patients	NOUN	O	O
.	PUNCT	O	O

-DOCSTART- (16418614)

Here	ADV	O	O
,	PUNCT	O	O
we	PRON	O	O
describe	VERB	O	O
a	DET	O	O
case	NOUN	O	O
of	ADP	O	O
severe	ADJ	O	O
masseter	NOUN	O	B-Entity
muscle	NOUN	O	I-Entity
rigidity	NOUN	O	I-Entity
(	PUNCT	O	O
jaw	NOUN	O	B-Entity
of	ADP	O	I-Entity
steel	NOUN	O	I-Entity
)	PUNCT	O	O
after	ADP	O	O
succinylcholine	NOUN	O	I-Entity
(	PUNCT	O	O
Sch	PROPN	O	I-Entity
)	PUNCT	O	O
administration	NOUN	O	O
during	ADP	O	O
general	ADJ	O	O
anesthetic	NOUN	O	O
management	NOUN	O	O
for	ADP	O	O
rigid	ADJ	O	O
bronchoscopic	NOUN	O	O
removal	NOUN	O	O
of	ADP	O	O
a	DET	O	O
tracheal	ADJ	O	O
foreign	ADJ	O	O
body	NOUN	O	O
.	PUNCT	O	O


The	DET	O	O
role	NOUN	O	O
of	ADP	O	O
epinephrine	NOUN	O	I-Entity
in	ADP	O	O
eliciting	VERB	O	O
myocardial	ADJ	O	B-Entity
ischemia	NOUN	O	I-Entity
was	VERB	O	O
examined	VERB	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
coronary	ADJ	O	B-Entity
artery	NOUN	O	I-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O

Such	ADJ	O	O
contralateral	ADJ	O	B-Entity
rotation	NOUN	O	I-Entity
may	VERB	O	O
result	VERB	O	O
from	ADP	O	O
either	DET	O	O
degeneration	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
breakdown	NOUN	O	O
of	ADP	O	O
the	DET	O	O
DA	PROPN	O	O
pool	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
lesion	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
increase	NOUN	O	O
of	ADP	O	O
DA	PROPN	O	O
turnover	NOUN	O	O
in	ADP	O	O
the	DET	O	O
spared	VERB	O	O
neurons	NOUN	O	O
.	PUNCT	O	O

-DOCSTART- (3001299)

Biphasic	ADJ	O	O
response	NOUN	O	O
of	ADP	O	O
the	DET	O	O
SA	PROPN	O	O
node	NOUN	O	O
of	ADP	O	O
the	DET	O	O
dog	NOUN	O	O
heart	NOUN	O	O
in	ADP	O	O
vivo	NOUN	O	O
to	ADP	O	O
selective	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
ketamine	NOUN	O	I-Entity
.	PUNCT	O	O


Chloroquine	PROPN	O	I-Entity
related	ADJ	O	O
complete	ADJ	O	O
heart	NOUN	O	B-Entity
block	NOUN	O	I-Entity
with	ADP	O	O
blindness	NOUN	O	I-Entity
:	PUNCT	O	O
case	NOUN	O	O
report	NOUN	O	O
.	PUNCT	O	O

IIIB	PROPN	O	O
or	CCONJ	O	O
IV	PROPN	O	O
non	ADJ	O	B-Entity
-	PUNCT	O	I-Entity
small	ADJ	O	I-Entity
cell	NOUN	O	I-Entity
lung	NOUN	O	I-Entity
cancer	NOUN	O	I-Entity
(	PUNCT	O	O
NSCLC	PROPN	O	I-Entity
)	PUNCT	O	O
reported	VERB	O	O
response	NOUN	O	O
rates	NOUN	O	O
of	ADP	O	O
21%	NUM	O	O
and	CCONJ	O	O
24%	NUM	O	O
.	PUNCT	O	O

Further	ADJ	O	O
phase	NOUN	O	O
II	PROPN	O	O
studies	NOUN	O	O
with	ADP	O	O
paclitaxel	NOUN	O	I-Entity
combined	VERB	O	O
with	ADP	O	O
other	ADJ	O	O
drugs	NOUN	O	O
active	ADJ	O	O
against	ADP	O	O
NSCLC	PROPN	O	I-Entity
are	VERB	O	O
indicated	VERB	O	O
,	PUNCT	O	O
and	CCONJ	O	O
phase	NOUN	O	O
III	NUM	O	O
studies	NOUN	O	O
comparing	VERB	O	O
paclitaxel	NOUN	O	I-Entity
with	ADP	O	O
standard	NOUN	O	O
chemotherapy	NOUN	O	O
remain	VERB	O	O
to	PART	O	O
be	VERB	O	O
completed	VERB	O	O
.	PUNCT	O	O

Although	ADP	O	O
large	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
amiodarone	NOUN	O	I-Entity
is	VERB	O	O
highly	ADV	O	O
effective	ADJ	O	O
in	ADP	O	O
the	DET	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
treatment	NOUN	O	O
of	ADP	O	O
VT	PROPN	O	I-Entity
or	CCONJ	O	O
VF	PROPN	O	I-Entity
refractory	NOUN	O	O
to	ADP	O	O
conventional	ADJ	O	O
antiarrhythmic	ADJ	O	O
drugs	NOUN	O	O
,	PUNCT	O	O
it	PRON	O	O
causes	VERB	O	O
significant	ADJ	O	O
toxicity	NOUN	O	I-Entity
in	ADP	O	O
approximately	ADV	O	O
50%	NUM	O	O
of	ADP	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Two	NUM	O	O
interventions	NOUN	O	O
were	VERB	O	O
studied	VERB	O	O
that	ADJ	O	O
have	VERB	O	O
been	VERB	O	O
shown	VERB	O	O
previously	ADV	O	O
to	PART	O	O
improve	VERB	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
with	ADP	O	O
calcium	NOUN	O	I-Entity
channel	NOUN	O	O
blocker	NOUN	O	O
overdose	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
dose	NOUN	O	O
was	VERB	O	O
escalated	VERB	O	O
from	ADP	O	O
100	NUM	O	O
to	ADP	O	O
200	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
m2/d	NOUN	O	O
until	ADP	O	O
dose	NOUN	O	O
-	PUNCT	O	O
limiting	VERB	O	O
toxicity	NOUN	O	I-Entity
(	PUNCT	O	O
DLT	PROPN	O	O
)	PUNCT	O	O
was	VERB	O	O
observed	VERB	O	O
.	PUNCT	O	O

Electrocardiographic	ADJ	O	O
changes	NOUN	O	O
and	CCONJ	O	O
cardiac	ADJ	O	B-Entity
arrhythmias	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
receiving	VERB	O	O
psychotropic	ADJ	O	O
drugs	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
ventricular	ADJ	O	B-Entity
arrhythmias	NOUN	O	I-Entity
responded	VERB	O	O
to	ADP	O	O
intravenous	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
lidocaine	NOUN	O	I-Entity
and	CCONJ	O	O
to	PART	O	O
direct	VERB	O	O
current	ADJ	O	O
electric	ADJ	O	O
shock	NOUN	O	O
;	PUNCT	O	O
ventricular	ADJ	O	O
pacing	NOUN	O	O
was	VERB	O	O
required	VERB	O	O
in	ADP	O	O
some	DET	O	O
instances	NOUN	O	O
and	CCONJ	O	O
intravenous	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
propranolol	NOUN	O	I-Entity
combined	VERB	O	O
with	ADP	O	O
ventricular	ADJ	O	O
pacing	NOUN	O	O
in	ADP	O	O
one	NUM	O	O
.	PUNCT	O	O

Prescription	NOUN	O	O
of	ADP	O	O
crocin	NOUN	O	I-Entity
in	ADP	O	O
each	DET	O	O
dose	NOUN	O	O
was	VERB	O	O
repeated	VERB	O	O
once	ADV	O	O
for	ADP	O	O
two	NUM	O	O
days	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
addition	NOUN	O	O
,	PUNCT	O	O
tacrine	NOUN	O	I-Entity
-	PUNCT	O	O
loaded	VERB	O	O
nanoparticles	NOUN	O	O
administration	NOUN	O	O
induced	VERB	O	O
damage	NOUN	O	B-Entity
of	ADP	O	I-Entity
neuronal	ADJ	O	I-Entity
cells	NOUN	O	I-Entity
in	ADP	O	O
CA1	PROPN	O	O
field	NOUN	O	O
of	ADP	O	O
the	DET	O	O
hippocampus	NOUN	O	O
in	ADP	O	O
all	DET	O	O
treated	VERB	O	O
animals	NOUN	O	O
,	PUNCT	O	O
while	ADP	O	O
the	DET	O	O
saline	ADJ	O	O
solution	NOUN	O	O
of	ADP	O	O
tacrine	NOUN	O	I-Entity
only	ADV	O	O
in	ADP	O	O
60%	NUM	O	O
of	ADP	O	O
animals	NOUN	O	O
.	PUNCT	O	O

Moreover	ADV	O	O
,	PUNCT	O	O
M(3)-muscarinic	ADJ	O	O
acetylcholine	NOUN	O	I-Entity
receptor	NOUN	O	O
(	PUNCT	O	O
mAChR	PROPN	O	O
)	PUNCT	O	O

-DOCSTART- (17786501)

Acute	PROPN	O	B-Entity
experimental	ADJ	O	I-Entity
models	NOUN	O	I-Entity
of	ADP	O	I-Entity
renal	ADJ	O	I-Entity
damage	NOUN	O	I-Entity
to	ADP	O	O
the	DET	O	O
proximal	ADJ	O	O
tubular	NOUN	O	O
,	PUNCT	O	O
glomerular	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
papillary	ADJ	O	O
regions	NOUN	O	O
of	ADP	O	O
the	DET	O	O
rat	NOUN	O	O
were	VERB	O	O
produced	VERB	O	O
by	ADP	O	O
administration	NOUN	O	O
of	ADP	O	O
hexachloro-1:3-butadiene	NOUN	O	I-Entity
(	PUNCT	O	O
HCBD	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
puromycin	NOUN	O	B-Entity
aminonucleoside	NOUN	O	I-Entity
(	PUNCT	O	O
PAN	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
2-bromoethylamine	NUM	O	I-Entity
(	PUNCT	O	O
BEA	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

At	ADP	O	O
autopsy	NOUN	O	O
,	PUNCT	O	O
analysis	NOUN	O	O
of	ADP	O	O
liver	NOUN	O	O
parenchyma	NOUN	O	O
revealed	VERB	O	O
rich	ADJ	O	O
portal	ADJ	O	O
inflammatory	ADJ	O	O
infiltrate	NOUN	O	O
,	PUNCT	O	O
which	ADJ	O	O
consisted	VERB	O	O
of	ADP	O	O
mixed	ADJ	O	O
eosinophil	NOUN	O	O
and	CCONJ	O	O
monocyte	NOUN	O	O
cells	NOUN	O	O
,	PUNCT	O	O
associated	VERB	O	O
with	ADP	O	O
several	ADJ	O	O
foci	NOUN	O	O
of	ADP	O	O
necrosis	NOUN	O	I-Entity
surrounded	VERB	O	O
by	ADP	O	O
a	DET	O	O
hard	ADJ	O	O
ring	NOUN	O	O
of	ADP	O	O
non	ADJ	O	O
-	PUNCT	O	O
specific	ADJ	O	O
granulomatous	ADJ	O	O
tissue	NOUN	O	O
.	PUNCT	O	O

Despite	ADP	O	O
stopping	VERB	O	O
ethambutol	NOUN	O	I-Entity
on	ADP	O	O
diagnosis	NOUN	O	O
,	PUNCT	O	O
visual	ADJ	O	O
function	NOUN	O	O
continued	VERB	O	O
to	PART	O	O
deteriorate	VERB	O	O
for	ADP	O	O
a	DET	O	O
few	ADJ	O	O
months	NOUN	O	O
.	PUNCT	O	O

Tolerability	NOUN	O	O
of	ADP	O	O
nimesulide	NOUN	O	I-Entity
and	CCONJ	O	O
paracetamol	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
NSAID	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
urticaria	NOUN	O	I-Entity
/	SYM	O	O
angioedema	NOUN	O	I-Entity
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
reaction	NOUN	O	O
to	ADP	O	O
these	DET	O	O
alternative	ADJ	O	O
study	NOUN	O	O
drugs	NOUN	O	O
is	VERB	O	O
statistically	ADV	O	O
increased	VERB	O	O
by	ADP	O	O
a	DET	O	O
history	NOUN	O	O
of	ADP	O	O
chronic	ADJ	O	O
urticaria	NOUN	O	I-Entity
and	CCONJ	O	O
,	PUNCT	O	O
above	ADV	O	O
all	DET	O	O
,	PUNCT	O	O
by	ADP	O	O
a	DET	O	O
history	NOUN	O	O
of	ADP	O	O
NSAID	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
angioedema	NOUN	O	I-Entity
.	PUNCT	O	O

Epicardial	ADJ	O	O
mapping	NOUN	O	O
with	ADP	O	O
240	NUM	O	O
epicardial	ADJ	O	O
electrodes	NOUN	O	O
was	VERB	O	O
used	VERB	O	O
to	PART	O	O
evaluate	VERB	O	O
activation	NOUN	O	O
during	ADP	O	O
AF	PROPN	O	I-Entity
.	PUNCT	O	O

-DOCSTART- (8742498)

Cibenzoline	PROPN	O	I-Entity
suppressed	VERB	O	O
all	ADJ	O	O
the	DET	O	O
arrhythmias	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
minimum	NOUN	O	O
effective	ADJ	O	O
plasma	NOUN	O	O
concentrations	NOUN	O	O
for	ADP	O	O
arrhythmias	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
24-h	NUM	O	O
coronary	ADJ	O	O
ligation	NOUN	O	O
,	PUNCT	O	O
48-h	NUM	O	O
coronary	ADJ	O	O
ligation	NOUN	O	O
,	PUNCT	O	O
digitalis	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
adrenaline	NOUN	O	I-Entity
were	VERB	O	O
1.9	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

Second	ADV	O	O
,	PUNCT	O	O
a	DET	O	O
stereotactic	ADJ	O	O
injection	NOUN	O	O
of	ADP	O	O
collagenase	NOUN	O	O
was	VERB	O	O
administered	VERB	O	O
to	PART	O	O
induce	VERB	O	O
hemorrhage	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
right	NOUN	O	O
striatum	NOUN	O	O
.	PUNCT	O	O


OBJECTIVES	NOUN	O	O
:	PUNCT	O	O
To	PART	O	O
study	VERB	O	O
the	DET	O	O
urinary	ADJ	O	O
symptoms	NOUN	O	O
and	CCONJ	O	O
quality	NOUN	O	O
of	ADP	O	O
life	NOUN	O	O
changes	NOUN	O	O
in	ADP	O	O
Thai	PROPN	O	O
women	NOUN	O	O
with	ADP	O	O
overactive	ADJ	O	B-Entity
bladder	NOUN	O	I-Entity
(	PUNCT	O	O
OAB	PROPN	O	I-Entity
)	PUNCT	O	O
after	ADP	O	O
tolterodine	NOUN	O	I-Entity
treatment	NOUN	O	O
.	PUNCT	O	O


A	DET	O	O
phase	NOUN	O	O
II	PROPN	O	O
study	NOUN	O	O
of	ADP	O	O
thalidomide	NOUN	O	I-Entity
in	ADP	O	O
advanced	ADJ	O	O
metastatic	ADJ	O	O
renal	ADJ	O	B-Entity
cell	NOUN	O	I-Entity
carcinoma	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
indicates	VERB	O	O
that	ADP	O	O
NO	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
immediate	ADJ	O	O
headache	NOUN	O	I-Entity
is	VERB	O	O
not	ADV	O	O
associated	VERB	O	O
with	ADP	O	O
release	NOUN	O	O
of	ADP	O	O
CGRP	PROPN	O	O
.	PUNCT	O	O

When	ADV	O	O
DSE	PROPN	O	O
is	VERB	O	O
performed	VERB	O	O
to	PART	O	O
evaluate	VERB	O	O
coronary	ADJ	O	B-Entity
artery	NOUN	O	I-Entity
disease	NOUN	O	I-Entity
,	PUNCT	O	O
not	ADV	O	O
only	ADV	O	O
fixed	VERB	O	O
coronary	ADJ	O	B-Entity
stenosis	NOUN	O	I-Entity
,	PUNCT	O	O
but	CCONJ	O	O
also	ADV	O	O
coronary	ADJ	O	B-Entity
spasm	NOUN	O	I-Entity
should	VERB	O	O
be	VERB	O	O
considered	VERB	O	O
as	ADP	O	O
a	DET	O	O
genesis	NOUN	O	O
of	ADP	O	O
asynergy	NOUN	O	O
.	PUNCT	O	O

Because	ADP	O	O
uncontrolled	ADJ	O	O
echocardiographic	ADJ	O	O
surveys	NOUN	O	O
suggested	VERB	O	O
that	ADP	O	O
up	ADP	O	O
to	PART	O	O
30%	NUM	O	O
to	ADP	O	O
38%	NUM	O	O
of	ADP	O	O
users	NOUN	O	O
of	ADP	O	O
fenfluramine	NOUN	O	I-Entity
and	CCONJ	O	O
dexfenfluramine	NOUN	O	I-Entity
had	VERB	O	O
valvular	ADJ	O	B-Entity
disease	NOUN	O	I-Entity
,	PUNCT	O	O
these	DET	O	O
drugs	NOUN	O	O
were	VERB	O	O
withdrawn	VERB	O	O
from	ADP	O	O
the	DET	O	O
market	NOUN	O	O
.	PUNCT	O	O

PATIENTS	NOUN	O	O
:	PUNCT	O	O
46	NUM	O	O
patients	NOUN	O	O
who	NOUN	O	O
used	VERB	O	O
fenfluramine	NOUN	O	I-Entity
or	CCONJ	O	O
dexfenfluramine	NOUN	O	I-Entity
for	ADP	O	O
14	NUM	O	O
days	NOUN	O	O
or	CCONJ	O	O
more	ADJ	O	O
and	CCONJ	O	O
had	VERB	O	O
echocardiograms	NOUN	O	O
obtained	VERB	O	O
before	ADP	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

Univariate	PROPN	O	O
and	CCONJ	O	O
adjusted	VERB	O	O
analyses	NOUN	O	O
showed	VERB	O	O
that	ADP	O	O
the	DET	O	O
risk	NOUN	O	O
increased	VERB	O	O
with	ADP	O	O
the	DET	O	O
length	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.0001	NUM	O	O
)	PUNCT	O	O
or	CCONJ	O	O
the	DET	O	O
cumulative	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
tamoxifen	NOUN	O	I-Entity
received	VERB	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.0001	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
irrespective	ADV	O	O
of	ADP	O	O
the	DET	O	O
daily	ADJ	O	O
dose	NOUN	O	O
.	PUNCT	O	O

Twenty	NUM	O	O
-	PUNCT	O	O
four	NUM	O	O
patients	NOUN	O	O
were	VERB	O	O
anaesthetized	VERB	O	O
for	ADP	O	O
middle	ADJ	O	O
-	PUNCT	O	O
ear	NOUN	O	O
surgery	NOUN	O	O
with	ADP	O	O
deliberate	ADJ	O	O
hypotension	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
labetalol	NOUN	O	I-Entity
with	ADP	O	O
isoflurane	NOUN	O	I-Entity
(	PUNCT	O	O
hypotensive	ADJ	O	I-Entity
group	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
maximum	ADJ	O	O
change	NOUN	O	O
in	ADP	O	O
threshold	NOUN	O	O
was	VERB	O	O
35	NUM	O	O
dB	NOUN	O	O
at	ADP	O	O
6	NUM	O	O
kHz	NOUN	O	O
measured	VERB	O	O
at	ADP	O	O
the	DET	O	O
end	NOUN	O	O
of	ADP	O	O
the	DET	O	O
continuous	ADJ	O	O
infusion	NOUN	O	O
of	ADP	O	O
bupivacaine	NOUN	O	I-Entity
.	PUNCT	O	O

IBPB	NOUN	O	O
may	VERB	O	O
cause	VERB	O	O
transient	ADJ	O	O
auditory	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
ipsilateral	ADJ	O	O
ear	NOUN	O	O
,	PUNCT	O	O
possibly	ADV	O	O
via	ADP	O	O
an	DET	O	O
effect	NOUN	O	O
on	ADP	O	O
sympathetic	ADJ	O	O
innervation	NOUN	O	O
.	PUNCT	O	O

Midazolam	PROPN	O	I-Entity
is	VERB	O	O
a	DET	O	O
new	ADJ	O	O
alternative	NOUN	O	O
agent	NOUN	O	O
for	ADP	O	O
induction	NOUN	O	O
in	ADP	O	O
combination	NOUN	O	O
anaesthesia	NOUN	O	O
.	PUNCT	O	O

Histologically	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
myocardial	ADJ	O	B-Entity
lesions	NOUN	O	I-Entity
resembled	VERB	O	O
those	DET	O	O
found	VERB	O	O
in	ADP	O	O
human	ADJ	O	O
anthracycline	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cardiomyopathy	NOUN	O	I-Entity
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
recommended	VERB	O	O
that	ADP	O	O
doxorubicin	NOUN	O	I-Entity
dosage	NOUN	O	O
be	VERB	O	O
sharply	ADV	O	O
restricted	VERB	O	O
in	ADP	O	O
children	NOUN	O	O
with	ADP	O	O
Wilms	PROPN	O	B-Entity
tumor	NOUN	O	I-Entity
of	ADP	O	O
the	DET	O	O
left	ADJ	O	O
kidney	NOUN	O	O
who	NOUN	O	O
receive	VERB	O	O
postoperative	ADJ	O	O
irradiation	NOUN	O	O
.	PUNCT	O	O

Preliminary	ADJ	O	O
results	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
testosterone	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
LW	PROPN	O	O
rats	NOUN	O	O
that	ADJ	O	O
were	VERB	O	O
fed	VERB	O	O
the	DET	O	O
same	ADJ	O	O
diet	NOUN	O	O
,	PUNCT	O	O
which	ADJ	O	O
was	VERB	O	O
supplemented	VERB	O	O
with	ADP	O	O
corn	NOUN	O	O
oil	NOUN	O	O
up	PART	O	O
to	ADP	O	O
20%	NUM	O	O
fat	NOUN	O	O
,	PUNCT	O	O
developed	VERB	O	O
prostate	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
after	ADP	O	O
intervals	NOUN	O	O
of	ADP	O	O
6	NUM	O	O
-	SYM	O	O
12	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

-DOCSTART- (2466960)

Ifosfamide	PROPN	O	I-Entity
is	VERB	O	O
a	DET	O	O
known	VERB	O	O
nephrotoxic	ADJ	O	I-Entity
drug	NOUN	O	O
with	ADP	O	O
demonstrated	VERB	O	O
tubulopathies	NOUN	O	I-Entity
.	PUNCT	O	O

Clinicians	NOUN	O	O
are	VERB	O	O
exhorted	VERB	O	O
to	PART	O	O
pay	VERB	O	O
close	ADJ	O	O
attention	NOUN	O	O
when	ADV	O	O
initiating	VERB	O	O
levofloxacin	NOUN	O	I-Entity
therapy	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
taking	VERB	O	O
medications	NOUN	O	O
with	ADP	O	O
epileptogenic	ADJ	O	O
properties	NOUN	O	O
that	ADJ	O	O
are	VERB	O	O
CYP1A2	ADJ	O	O
substrates	NOUN	O	O
.	PUNCT	O	O

Eight	NUM	O	O
patients	NOUN	O	O
were	VERB	O	O
hospitalised	VERB	O	O
,	PUNCT	O	O
two	NUM	O	O
in	ADP	O	O
hepatic	ADJ	O	B-Entity
failure	NOUN	O	I-Entity
-	PUNCT	O	O
one	NUM	O	O
died	VERB	O	O
after	ADP	O	O
a	DET	O	O
liver	NOUN	O	O
transplant	NOUN	O	O
.	PUNCT	O	O

:	PUNCT	O	O
The	DET	O	O
use	NOUN	O	O
of	ADP	O	O
iodinated	ADJ	O	O
contrast	NOUN	O	O
medium	NOUN	O	O
can	VERB	O	O
result	VERB	O	O
in	ADP	O	O
nephropathy	NOUN	O	I-Entity
.	PUNCT	O	O

-DOCSTART- (8911359)

Cyclophosphamide	PROPN	O	I-Entity
associated	VERB	O	O
bladder	NOUN	O	B-Entity
tumor	NOUN	O	I-Entity
is	VERB	O	O
an	DET	O	O
aggressive	ADJ	O	O
disease	NOUN	O	O
.	PUNCT	O	O

Thirteen	NUM	O	O
of	ADP	O	O
these	DET	O	O
patients	NOUN	O	O
experienced	VERB	O	O
pain	NOUN	O	B-Entity
in	ADP	O	I-Entity
the	DET	O	I-Entity
legs	NOUN	O	I-Entity
and/or	CCONJ	O	I-Entity
back	ADV	O	I-Entity
after	ADP	O	O
recovery	NOUN	O	O
from	ADP	O	O
anaesthesia	NOUN	O	O
.	PUNCT	O	O

Hallucinations	NOUN	O	I-Entity
and	CCONJ	O	O
ifosfamide	ADV	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
neurotoxicity	NOUN	O	I-Entity
.	PUNCT	O	O

-DOCSTART- (3950060)

Despite	ADP	O	O
this	DET	O	O
improvement	NOUN	O	O
in	ADP	O	O
late	ADJ	O	O
renal	ADJ	O	O
function	NOUN	O	O
,	PUNCT	O	O
group	NOUN	O	O
II	PROPN	O	O
still	ADV	O	O
shows	VERB	O	O
a	DET	O	O
slow	ADJ	O	O
rise	NOUN	O	O
in	ADP	O	O
serum	NOUN	O	O
creatinine	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
PMs	PROPN	O	O
,	PUNCT	O	O
metoprolol	NOUN	O	I-Entity
increased	VERB	O	O
the	DET	O	O
terbutaline	NOUN	O	I-Entity
area	NOUN	O	O
under	ADP	O	O
the	DET	O	O
plasma	NOUN	O	O
concentration	NOUN	O	O
vs.	ADP	O	O
time	NOUN	O	O
curve	NOUN	O	O
(	PUNCT	O	O
+	SYM	O	O
67%	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
eluate	NOUN	O	O
also	ADV	O	O
reacted	VERB	O	O
weakly	ADV	O	O
with	ADP	O	O
red	ADJ	O	O
blood	NOUN	O	O
cells	NOUN	O	O
in	ADP	O	O
the	DET	O	O
absence	NOUN	O	O
of	ADP	O	O
cefotetan	NOUN	O	I-Entity
,	PUNCT	O	O
suggesting	VERB	O	O
the	DET	O	O
concomitant	ADJ	O	O
formation	NOUN	O	O
of	ADP	O	O
warm	ADJ	O	O
-	PUNCT	O	O
reactive	ADJ	O	O
autoantibodies	NOUN	O	O
.	PUNCT	O	O

-DOCSTART- (21418164)

Steroids	NOUN	O	I-Entity
with	ADP	O	O
the	DET	O	O
3-hydroxy	NUM	O	O
group	NOUN	O	O
in	ADP	O	O
the	DET	O	O
alpha	NOUN	O	O
-	PUNCT	O	O
position	NOUN	O	O
and	CCONJ	O	O
5-H	NUM	O	O
in	ADP	O	O
the	DET	O	O
alpha-	NOUN	O	O
or	CCONJ	O	O
beta	NOUN	O	O
-	PUNCT	O	O
configurations	NOUN	O	O
were	VERB	O	O
highly	ADV	O	O
effective	ADJ	O	O
in	ADP	O	O
protecting	VERB	O	O
against	ADP	O	O
pilocarpine	NOUN	O	I-Entity
(	PUNCT	O	O
416	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
,	PUNCT	O	O
s.c.)-induced	VERB	O	O
limbic	ADJ	O	O
motor	NOUN	O	O
seizures	NOUN	O	I-Entity
and	CCONJ	O	O
status	NOUN	O	B-Entity
epilepticus	NOUN	O	I-Entity
(	PUNCT	O	O
ED50	PROPN	O	O
values	NOUN	O	O
,	PUNCT	O	O
7.0	NUM	O	O
-	SYM	O	O
18.7	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
,	PUNCT	O	O
i.p	PROPN	O	O
.	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Twenty	NUM	O	O
-	PUNCT	O	O
three	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
38%	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
15	NUM	O	O
(	PUNCT	O	O
26%	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
combination	NOUN	O	O
and	CCONJ	O	O
zidovudine	NOUN	O	I-Entity
groups	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
discontinued	VERB	O	O
therapy	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.15	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

6.33	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
suggesting	VERB	O	O
an	DET	O	O
effective	ADJ	O	O
sphincter	NOUN	O	O
-	PUNCT	O	O
relaxing	VERB	O	O
effect	NOUN	O	O
of	ADP	O	O
glyceryl	NOUN	O	B-Entity
trinitrate	NOUN	O	I-Entity
.	PUNCT	O	O

Effects	NOUN	O	O
of	ADP	O	O
acute	ADJ	O	O
steroid	NOUN	O	I-Entity
administration	NOUN	O	O
on	ADP	O	O
ventilatory	NOUN	O	O
and	CCONJ	O	O
peripheral	ADJ	O	O
muscles	NOUN	O	O
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
a	DET	O	O
similar	ADJ	O	O
loss	NOUN	O	B-Entity
in	ADP	O	I-Entity
body	NOUN	O	I-Entity
weight	NOUN	O	I-Entity
.	PUNCT	O	O

p	X	O	O
<	X	O	O
0.05	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
T	NOUN	O	I-Entity
group	NOUN	O	O
(	PUNCT	O	O
765	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

A	DET	O	O
seventy	NUM	O	O
-	PUNCT	O	O
eight	NUM	O	O
-	PUNCT	O	O
year	NOUN	O	O
-	PUNCT	O	O
old	ADJ	O	O
woman	NOUN	O	O
presented	VERB	O	O
with	ADP	O	O
complete	ADJ	O	O
heart	NOUN	O	B-Entity
block	NOUN	O	I-Entity
and	CCONJ	O	O
refractory	ADJ	O	O
hypotension	NOUN	O	I-Entity
two	NUM	O	O
days	NOUN	O	O
after	ADP	O	O
a	DET	O	O
therapeutic	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
sustained	VERB	O	O
-	PUNCT	O	O
release	NOUN	O	O
verapamil	NOUN	O	I-Entity
with	ADP	O	O
concomitant	ADJ	O	O
use	NOUN	O	O
of	ADP	O	O
metoprolol	NOUN	O	I-Entity
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
shortly	ADV	O	O
after	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
intravenous	ADJ	O	O
calcium	NOUN	O	B-Entity
chloride	NOUN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
refractory	ADJ	O	O
hypotension	NOUN	O	I-Entity
and	CCONJ	O	O
complete	ADJ	O	O
heart	NOUN	O	B-Entity
block	NOUN	O	I-Entity
resolved	VERB	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
:	PUNCT	O	O
Thirty	NUM	O	O
-	PUNCT	O	O
seven	NUM	O	O
of	ADP	O	O
160	NUM	O	O
patients	NOUN	O	O
who	NOUN	O	O
had	VERB	O	O
HCV	PROPN	O	O
-	PUNCT	O	O
genotype	NOUN	O	O
1b	NUM	O	O
,	PUNCT	O	O
had	VERB	O	O
high	ADJ	O	O
virus	NOUN	O	O
load	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
received	VERB	O	O
24-week	NUM	O	O
combination	NOUN	O	O
therapy	NOUN	O	O
developed	VERB	O	O
anemia	NOUN	O	I-Entity
with	ADP	O	O
hemoglobin	NOUN	O	O
level	NOUN	O	O
<	X	O	O
10	NUM	O	O
g	NOUN	O	O
/	SYM	O	O
dl	NOUN	O	O
or	CCONJ	O	O
anemia	NOUN	O	I-Entity
-	PUNCT	O	O
related	VERB	O	O
signs	NOUN	O	O
during	ADP	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

their	ADJ	O	O
<	X	O	O
8.5	NUM	O	O
g	NOUN	O	O
/	SYM	O	O
dl	ADP	O	O
hemoglobin	NOUN	O	O
values	NOUN	O	O
decreased	VERB	O	O
to	ADP	O	O
or	CCONJ	O	O
anemia	NOUN	O	I-Entity
-	PUNCT	O	O
related	VERB	O	O
severe	ADJ	O	O
side	NOUN	O	O
effects	NOUN	O	O
occurred	VERB	O	O
(	PUNCT	O	O
group	NOUN	O	O
B	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
decreased	ADJ	O	O
abundance	NOUN	O	O
of	ADP	O	O
NHE3	PROPN	O	O
,	PUNCT	O	O
BSC-1	PROPN	O	O
,	PUNCT	O	O
TSC	PROPN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
Na	PROPN	O	I-Entity
-	PUNCT	O	O
K	PROPN	O	I-Entity
-	PUNCT	O	O
ATPase	PROPN	O	O
may	VERB	O	O
play	VERB	O	O
a	DET	O	O
compensatory	ADJ	O	O
role	NOUN	O	O
to	PART	O	O
promote	VERB	O	O
sodium	NOUN	O	I-Entity
excretion	NOUN	O	O
.	PUNCT	O	O

-DOCSTART- (14745746)

Verbal	ADJ	O	O
memory	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
especially	ADV	O	O
sensitive	ADJ	O	O
to	ADP	O	O
changes	NOUN	O	O
in	ADP	O	O
oestrogen	NOUN	O	I-Entity
levels	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
finding	VERB	O	O
commonly	ADV	O	O
reported	VERB	O	O
in	ADP	O	O
studies	NOUN	O	O
of	ADP	O	O
hormone	NOUN	O	O
replacement	NOUN	O	O
therapy	NOUN	O	O
in	ADP	O	O
healthy	ADJ	O	O
women	NOUN	O	O
.	PUNCT	O	O

dopamine	NOUN	O	I-Entity
receptor	NOUN	O	O
-	PUNCT	O	O
stimulating	VERB	O	O
behavioral	ADJ	O	O
signs	NOUN	O	O
such	ADJ	O	O
as	ADP	O	O
stereotypy	NOUN	O	O
and	CCONJ	O	O
hyperlocomotion	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Symptomatic	ADJ	O	O
adverse	ADJ	O	O
effects	NOUN	O	O
were	VERB	O	O
present	ADJ	O	O
in	ADP	O	O
96%	NUM	O	O
of	ADP	O	O
subjects	NOUN	O	O
,	PUNCT	O	O
most	ADV	O	O
commonly	ADV	O	O
nausea	NOUN	O	I-Entity
(	PUNCT	O	O
64%	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
fatigue	NOUN	O	I-Entity
(	PUNCT	O	O
55%	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
headache	NOUN	O	I-Entity
(	PUNCT	O	O
49%	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Significant	ADJ	O	O
increases	NOUN	O	O
in	ADP	O	O
certain	ADJ	O	O
factors	NOUN	O	O
of	ADP	O	O
the	DET	O	O
blood	NOUN	O	B-Entity
coagulation	NOUN	O	I-Entity
and	CCONJ	O	O
fibrinolysin	NOUN	O	O
systems	NOUN	O	O
(	PUNCT	O	O
factors	NOUN	O	O
I	PRON	O	O
,	PUNCT	O	O
II	PROPN	O	O
,	PUNCT	O	O
VII	PROPN	O	O
,	PUNCT	O	O
VIII	PROPN	O	O
,	PUNCT	O	O
IX	PROPN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
X	PROPN	O	O
and	CCONJ	O	O
plasminogen	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
the	DET	O	O
treated	VERB	O	O
groups	NOUN	O	O
.	PUNCT	O	O

One	NUM	O	O
patient	NOUN	O	O
developed	VERB	O	O
retinopathy	ADJ	O	I-Entity
19	NUM	O	O
months	NOUN	O	O
after	ADP	O	O
she	PRON	O	O
began	VERB	O	O
therapy	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
another	DET	O	O
developed	VERB	O	O
thrombophlebitis	NOUN	O	I-Entity
after	ADP	O	O
27	NUM	O	O
months	NOUN	O	O
of	ADP	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

Over	ADP	O	O
the	DET	O	O
following	VERB	O	O
9	NUM	O	O
days	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
symptoms	NOUN	O	O
improved	VERB	O	O
and	CCONJ	O	O
plasma	NOUN	O	O
bilirubin	NOUN	O	I-Entity
levels	NOUN	O	O
were	VERB	O	O
normal	ADJ	O	O
after	ADP	O	O
12	NUM	O	O
weeks	NOUN	O	O
without	ADP	O	O
methimazole	NOUN	O	I-Entity
.	PUNCT	O	O

-DOCSTART- (10728962)

Induction	NOUN	O	O
by	ADP	O	O
paracetamol	NOUN	O	I-Entity
of	ADP	O	O
bladder	NOUN	O	B-Entity
and	CCONJ	O	I-Entity
liver	NOUN	O	I-Entity
tumours	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
rat	NOUN	O	O
.	PUNCT	O	O

Groups	NOUN	O	O
of	ADP	O	O
male	ADJ	O	O
and	CCONJ	O	O
female	ADJ	O	O
inbred	ADJ	O	O
Leeds	PROPN	O	O
strain	NOUN	O	O
rats	NOUN	O	O
were	VERB	O	O
fed	VERB	O	O
diets	NOUN	O	O
containing	VERB	O	O
either	CCONJ	O	O
0.5%	NUM	O	O
or	CCONJ	O	O
1.0%	NUM	O	O
paracetamol	NOUN	O	I-Entity
by	ADP	O	O
weight	NOUN	O	O
for	ADP	O	O
up	ADP	O	O
to	PART	O	O
18	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
novel	NOUN	O	O
anxiolytic	ADJ	O	O
drug	NOUN	O	O
,	PUNCT	O	O
buspirone	NOUN	O	I-Entity
,	PUNCT	O	O
reverses	VERB	O	O
catalepsy	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
haloperidol	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
possible	ADJ	O	O
utility	NOUN	O	O
of	ADP	O	O
chronic	ADJ	O	O
CBZ	NOUN	O	I-Entity
in	ADP	O	O
preventing	VERB	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
toxic	ADJ	O	O
side	NOUN	O	O
effects	NOUN	O	O
in	ADP	O	O
human	ADJ	O	O
cocaine	NOUN	O	I-Entity
users	NOUN	O	O
is	VERB	O	O
suggested	VERB	O	O
by	ADP	O	O
these	DET	O	O
data	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
remains	VERB	O	O
to	PART	O	O
be	VERB	O	O
directly	ADV	O	O
evaluated	VERB	O	O
.	PUNCT	O	O

Joint	ADJ	O	O
stiffness	NOUN	O	O
and	CCONJ	O	O
contractures	NOUN	O	I-Entity
also	ADV	O	O
improved	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
dose	NOUN	O	O
of	ADP	O	O
D	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
penicillamine	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
a	DET	O	O
favorable	ADJ	O	O
response	NOUN	O	O
was	VERB	O	O
as	ADV	O	O
low	ADJ	O	O
as	ADP	O	O
2	NUM	O	O
to	PART	O	O
5	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	NOUN	O	O
per	ADP	O	O
day	NOUN	O	O
given	VERB	O	O
over	ADP	O	O
a	DET	O	O
period	NOUN	O	O
ranging	VERB	O	O
from	ADP	O	O
15	NUM	O	O
to	ADP	O	O
53	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

D	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
Penicillamine	PROPN	O	I-Entity
caused	VERB	O	O
nephrotic	ADJ	O	B-Entity
syndrome	NOUN	O	I-Entity
in	ADP	O	O
1	NUM	O	O
patient	NOUN	O	O
and	CCONJ	O	O
milder	ADJ	O	O
reversible	ADJ	O	O
proteinuria	NOUN	O	I-Entity
in	ADP	O	O
3	NUM	O	O
other	ADJ	O	O
patients	NOUN	O	O
;	PUNCT	O	O
none	NOUN	O	O
developed	VERB	O	O
renal	ADJ	O	B-Entity
insufficiency	NOUN	O	I-Entity
.	PUNCT	O	O

Fenoldopam	PROPN	O	B-Entity
mesylate	NOUN	O	I-Entity
is	VERB	O	O
a	DET	O	O
specific	ADJ	O	O
DA1	PROPN	O	O
receptor	NOUN	O	O
agonist	NOUN	O	O
that	ADJ	O	O
lowers	VERB	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
by	ADP	O	O
vasodilatation	NOUN	O	O
.	PUNCT	O	O

Sodium	NOUN	O	O
nitroprusside	NOUN	O	I-Entity
is	VERB	O	O
a	DET	O	O
non	ADJ	O	O
-	PUNCT	O	O
selective	ADJ	O	O
arteriolar	NOUN	O	O
and	CCONJ	O	O
venous	ADJ	O	O
vasodilator	NOUN	O	O
that	ADJ	O	O
can	VERB	O	O
produce	VERB	O	O
redistribution	NOUN	O	O
of	ADP	O	O
blood	NOUN	O	O
flow	VERB	O	O
away	ADV	O	O
from	ADP	O	O
the	DET	O	O
kidney	NOUN	O	O
during	ADP	O	O
induced	VERB	O	O
hypotension	NOUN	O	I-Entity
.	PUNCT	O	O

Echocardiogram	PROPN	O	O
revealed	VERB	O	O
a	DET	O	O
normal	ADJ	O	O
ejection	NOUN	O	O
fraction	NOUN	O	O
and	CCONJ	O	O
a	DET	O	O
resolution	NOUN	O	O
of	ADP	O	O
the	DET	O	O
apical	ADJ	O	O
akinesis	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
our	ADJ	O	O
patient	NOUN	O	O
,	PUNCT	O	O
both	DET	O	O
supraphysiologic	ADJ	O	O
levels	NOUN	O	O
of	ADP	O	O
plasma	NOUN	O	O
catecholamines	NOUN	O	I-Entity
and	CCONJ	O	O
stress	NOUN	O	O
related	VERB	O	O
neuropeptides	NOUN	O	O
caused	VERB	O	O
by	ADP	O	O
cancer	NOUN	O	I-Entity
diagnosis	NOUN	O	O
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
chemotherapy	NOUN	O	O
may	VERB	O	O
have	VERB	O	O
contributed	VERB	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
ABS	PROPN	O	I-Entity
.	PUNCT	O	O

Reduction	NOUN	O	O
of	ADP	O	O
pain	NOUN	O	I-Entity
during	ADP	O	O
induction	NOUN	O	O
with	ADP	O	O
target	NOUN	O	O
-	PUNCT	O	O
controlled	VERB	O	O
propofol	NOUN	O	I-Entity
and	CCONJ	O	O
remifentanil	NOUN	O	I-Entity
.	PUNCT	O	O

Pain	PROPN	O	I-Entity
on	ADP	O	O
injection	NOUN	O	O
of	ADP	O	O
propofol	NOUN	O	I-Entity
is	VERB	O	O
unpleasant	ADJ	O	O
.	PUNCT	O	O

1%	NUM	O	O
in	ADP	O	O
1-day	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
control	NOUN	O	O
animals	NOUN	O	O
and	CCONJ	O	O
significantly	ADV	O	O
lower	ADJ	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	X	O	O
0.01	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
fluoxetine	NOUN	O	I-Entity
-	PUNCT	O	O
exposed	VERB	O	O
pups	NOUN	O	O
(	PUNCT	O	O
79	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O


In	ADP	O	O
this	DET	O	O
cross	NOUN	O	O
-	PUNCT	O	O
sectional	ADJ	O	O
study	NOUN	O	O
interview	NOUN	O	O
,	PUNCT	O	O
ECGs	NOUN	O	O
and	CCONJ	O	O
blood	NOUN	O	O
samples	NOUN	O	O
were	VERB	O	O
collected	VERB	O	O
in	ADP	O	O
a	DET	O	O
population	NOUN	O	O
of	ADP	O	O
adult	NOUN	O	O
heroin	NOUN	O	I-Entity
addicts	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
methadone	NOUN	O	I-Entity
or	CCONJ	O	O
buprenorphine	NOUN	O	I-Entity
on	ADP	O	O
a	DET	O	O
daily	ADJ	O	O
basis	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
he	PRON	O	O
achieved	VERB	O	O
complete	ADJ	O	O
remission	NOUN	O	O
,	PUNCT	O	O
he	PRON	O	O
received	VERB	O	O
high	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
cytosine	NOUN	O	B-Entity
arabinoside	NOUN	O	I-Entity
treatment	NOUN	O	O
(	PUNCT	O	O
2	NUM	O	O
g	NOUN	O	O
/	SYM	O	O
m2	NOUN	O	O
twice	ADV	O	O
a	DET	O	O
day	NOUN	O	O
for	ADP	O	O
5	NUM	O	O
days	NOUN	O	O
;	PUNCT	O	O
total	ADJ	O	O
,	PUNCT	O	O
20	NUM	O	O
g	NOUN	O	O
/	SYM	O	O
m2	NOUN	O	O
)	PUNCT	O	O
as	ADP	O	O
consolidation	NOUN	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

Atorvastatin	PROPN	O	I-Entity
prevented	VERB	O	O
and	CCONJ	O	O
reversed	VERB	O	O
dexamethasone	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hypertension	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
rat	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
anemia	NOUN	O	I-Entity
group	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
growth	NOUN	O	O
delay	NOUN	O	O
was	VERB	O	O
significantly	ADV	O	O
shorter	ADJ	O	O
compared	VERB	O	O
with	ADP	O	O
nonanemic	ADJ	O	O
controls	NOUN	O	O
(	PUNCT	O	O
13.3	NUM	O	O
days	NOUN	O	O
versus	ADP	O	O
8.6	NUM	O	O
days	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
50%	NUM	O	O
effective	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
d	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
tubocurarine	NOUN	O	I-Entity
(	PUNCT	O	O
microg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
tibialis	NOUN	O	O
muscle	NOUN	O	O
was	VERB	O	O
smaller	ADJ	O	O
in	ADP	O	O
the	DET	O	O
P10	PROPN	O	O
(	PUNCT	O	O
33.6	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

-DOCSTART- (10533019)

The	DET	O	O
emergency	NOUN	O	O
physician	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
aware	ADJ	O	O
that	ADP	O	O
life	NOUN	O	O
-	PUNCT	O	O
threatening	VERB	O	O
tetany	NOUN	O	I-Entity
may	VERB	O	O
accompany	VERB	O	O
the	DET	O	O
administration	NOUN	O	O
of	ADP	O	O
intravenous	ADJ	O	O
diltiazem	NOUN	O	I-Entity
and	CCONJ	O	O
that	ADP	O	O
calcium	NOUN	O	B-Entity
chloride	NOUN	O	I-Entity
may	VERB	O	O
be	VERB	O	O
a	DET	O	O
rapid	ADJ	O	O
and	CCONJ	O	O
effective	ADJ	O	O
remedy	NOUN	O	O
.	PUNCT	O	O

n	CCONJ	O	O
=	SYM	O	O
9	NUM	O	O
)	PUNCT	O	O
starting	VERB	O	O
immediately	ADV	O	O
after	ADP	O	O
the	DET	O	O
diagnosis	NOUN	O	O
of	ADP	O	O
aneurysmal	ADJ	O	I-Entity
SAH	PROPN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (8268147)



Gentamicin	PROPN	O	I-Entity
nephropathy	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
neonate	NOUN	O	O
.	PUNCT	O	O

When	ADV	O	O
the	DET	O	O
treatment	NOUN	O	O
last	ADJ	O	O
only	ADV	O	O
2	NUM	O	O
weeks	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
presence	NOUN	O	O
of	ADP	O	O
PB	PROPN	O	I-Entity
did	VERB	O	O
not	ADV	O	O
change	VERB	O	O
significantly	ADV	O	O
the	DET	O	O
last	ADJ	O	O
parameters	NOUN	O	O
.	PUNCT	O	O

DM	PROPN	O	I-Entity
rats	NOUN	O	O
with	ADP	O	O
mild	ADJ	O	O
glycosuria	NOUN	O	I-Entity
(	PUNCT	O	O
similar	ADJ	O	O
in	ADP	O	O
degree	NOUN	O	O
to	ADP	O	O
that	DET	O	O
of	ADP	O	O
the	DET	O	O
P	NOUN	O	I-Entity
treated	VERB	O	O
animals	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
also	ADV	O	O
studied	VERB	O	O
.	PUNCT	O	O

Tiapride	PROPN	O	I-Entity
in	ADP	O	O
levodopa	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
involuntary	ADJ	O	B-Entity
movements	NOUN	O	I-Entity
.	PUNCT	O	O

EEG	NOUN	O	O
recordings	NOUN	O	O
were	VERB	O	O
obtained	VERB	O	O
before	ADV	O	O
and	CCONJ	O	O
15	NUM	O	O
minutes	NOUN	O	O
following	VERB	O	O
penicillin	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
G	PROPN	O	I-Entity
injection	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
at	ADP	O	O
10th	ADJ	O	O
minutes	NOUN	O	O
following	VERB	O	O
each	DET	O	O
stimulus	NOUN	O	O
for	ADP	O	O
analysis	NOUN	O	O
in	ADP	O	O
terms	NOUN	O	O
of	ADP	O	O
frequency	NOUN	O	O
,	PUNCT	O	O
amplitude	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
power	NOUN	O	O
spectrum	NOUN	O	O
.	PUNCT	O	O

N	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
methyl	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
D	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
aspartate	NOUN	O	I-Entity
(	PUNCT	O	O
NMDA	PROPN	O	I-Entity
)	PUNCT	O	O


Pyrazinamide	PROPN	O	I-Entity
can	VERB	O	O
have	VERB	O	O
adverse	ADJ	O	O
effects	NOUN	O	O
such	ADJ	O	O
as	ADP	O	O
hepatic	ADJ	O	B-Entity
toxicity	NOUN	O	I-Entity
,	PUNCT	O	O
hyperuricemia	NOUN	O	I-Entity
or	CCONJ	O	O
digestive	ADJ	O	O
disorders	NOUN	O	O
.	PUNCT	O	O

Chronic	ADJ	O	O
T	NOUN	O	I-Entity
treatment	NOUN	O	O
significantly	ADV	O	O
decreased	VERB	O	O
5-HT	NUM	O	I-Entity
and	CCONJ	O	O
5-HIAA	NUM	O	I-Entity
in	ADP	O	O
certain	ADJ	O	O
brain	NOUN	O	O
areas	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
to	ADP	O	O
a	DET	O	O
much	ADV	O	O
lesser	ADJ	O	O
extent	NOUN	O	O
than	ADP	O	O
PCPA	PROPN	O	I-Entity
.	PUNCT	O	O

Based	VERB	O	O
on	ADP	O	O
these	DET	O	O
data	NOUN	O	O
,	PUNCT	O	O
it	PRON	O	O
can	VERB	O	O
be	VERB	O	O
speculated	VERB	O	O
that	ADP	O	O
pubertal	ADJ	O	O
AAS	PROPN	O	O
users	NOUN	O	O
with	ADP	O	O
low	ADJ	O	O
central	ADJ	O	O
5-HT	NOUN	O	I-Entity
may	VERB	O	O
be	VERB	O	O
especially	ADV	O	O
prone	ADJ	O	O
to	ADP	O	O
exhibit	VERB	O	O
aggressive	ADJ	O	B-Entity
behavior	NOUN	O	I-Entity
.	PUNCT	O	O

An	DET	O	O
82-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
man	NOUN	O	O
with	ADP	O	O
treatment	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
resistant	ADJ	O	I-Entity
depression	NOUN	O	I-Entity
and	CCONJ	O	O
early	ADJ	O	O
Alzheimer	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
was	VERB	O	O
started	VERB	O	O
on	ADP	O	O
methylphenidate	NOUN	O	I-Entity
.	PUNCT	O	O


We	PRON	O	O
recommend	VERB	O	O
that	ADP	O	O
hyperbaric	ADJ	O	O
lignocaine	NOUN	O	I-Entity
should	VERB	O	O
be	VERB	O	O
administered	VERB	O	O
in	ADP	O	O
concentrations	NOUN	O	O
not	ADV	O	O
greater	ADJ	O	O
than	ADP	O	O
2%	NUM	O	O
and	CCONJ	O	O
at	ADP	O	O
a	DET	O	O
total	ADJ	O	O
dose	NOUN	O	O
preferably	ADV	O	O
not	ADV	O	O
exceeding	VERB	O	O
60	NUM	O	O
mg	NOUN	O	O
.	PUNCT	O	O

Dexamethasone	PROPN	O	I-Entity
treatment	NOUN	O	O
of	ADP	O	O
isolated	ADJ	O	O
,	PUNCT	O	O
perfusion	NOUN	O	O
-	PUNCT	O	O
cultured	VERB	O	O
human	ADJ	O	O
eyes	NOUN	O	O
led	VERB	O	O
to	ADP	O	O
the	DET	O	O
generation	NOUN	O	O
of	ADP	O	O
ocular	ADJ	O	B-Entity
hypertension	NOUN	O	I-Entity
in	ADP	O	O
approximately	ADV	O	O
30%	NUM	O	O
of	ADP	O	O
the	DET	O	O
dexamethasone	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
eyes	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
important	ADJ	O	O
to	PART	O	O
recognize	VERB	O	O
this	DET	O	O
reaction	NOUN	O	O
when	ADV	O	O
it	PRON	O	O
occurs	VERB	O	O
and	CCONJ	O	O
to	PART	O	O
avoid	VERB	O	O
further	ADJ	O	O
quinine	NOUN	O	I-Entity
exposure	NOUN	O	O
,	PUNCT	O	O
since	ADP	O	O
the	DET	O	O
reaction	NOUN	O	O
seems	VERB	O	O
to	PART	O	O
be	VERB	O	O
recurrent	ADJ	O	O
.	PUNCT	O	O

The	DET	O	O
rate	NOUN	O	O
of	ADP	O	O
resolution	NOUN	O	O
of	ADP	O	O
the	DET	O	O
radiographic	ADJ	O	O
findings	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
helpful	ADJ	O	O
in	ADP	O	O
distinguishing	VERB	O	O
between	ADP	O	O
true	ADJ	O	O
pyeloureteritis	NOUN	O	B-Entity
cystica	NOUN	O	I-Entity
and	CCONJ	O	O
submucosal	NOUN	O	B-Entity
hemorrhage	NOUN	O	I-Entity
.	PUNCT	O	O

These	DET	O	O
cells	NOUN	O	O
proliferated	VERB	O	O
further	ADV	O	O
,	PUNCT	O	O
replacing	VERB	O	O
the	DET	O	O
most	ADJ	O	O
part	NOUN	O	O
of	ADP	O	O
the	DET	O	O
nodules	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
with	ADP	O	O
this	DET	O	O
process	NOUN	O	O
hepatomas	NOUN	O	I-Entity
appeared	VERB	O	O
to	PART	O	O
have	VERB	O	O
been	VERB	O	O
formed	VERB	O	O
.	PUNCT	O	O


Nicotine	ADJ	O	I-Entity
potentiation	NOUN	O	O
of	ADP	O	O
morphine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
catalepsy	NOUN	O	I-Entity
in	ADP	O	O
mice	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
was	VERB	O	O
concluded	VERB	O	O
that	ADP	O	O
morphine	NOUN	O	I-Entity
catalepsy	NOUN	O	I-Entity
can	VERB	O	O
be	VERB	O	O
elicited	VERB	O	O
by	ADP	O	O
opioid	ADJ	O	O
and	CCONJ	O	O
cholinergic	ADJ	O	O
receptors	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
potentiation	NOUN	O	O
of	ADP	O	O
morphine	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
nicotine	NOUN	O	I-Entity
may	VERB	O	O
also	ADV	O	O
be	VERB	O	O
mediated	VERB	O	O
through	ADP	O	O
cholinergic	ADJ	O	O
receptor	NOUN	O	O
mechanisms	NOUN	O	O
.	PUNCT	O	O

Cardiotoxicity	PROPN	O	I-Entity
was	VERB	O	O
defined	VERB	O	O
by	ADP	O	O
reductions	NOUN	O	O
in	ADP	O	O
left	VERB	O	O
-	PUNCT	O	O
ventricular	ADJ	O	O
ejection	NOUN	O	O
fraction	NOUN	O	O
,	PUNCT	O	O
assessed	VERB	O	O
by	ADP	O	O
serial	ADJ	O	O
multigated	VERB	O	O
radionuclide	NOUN	O	O
angiography	NOUN	O	O
scans	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
congestive	ADJ	O	B-Entity
heart	NOUN	O	I-Entity
failure	NOUN	O	I-Entity
(	PUNCT	O	O
CHF	PROPN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O


Cyclophosphamide	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cystitis	NOUN	O	I-Entity
in	ADP	O	O
freely	ADV	O	O
-	PUNCT	O	O
moving	VERB	O	O
conscious	ADJ	O	O
rats	NOUN	O	O
:	PUNCT	O	O
behavioral	ADJ	O	O
approach	NOUN	O	O
to	ADP	O	O
a	DET	O	O
new	ADJ	O	O
model	NOUN	O	O
of	ADP	O	O
visceral	ADJ	O	B-Entity
pain	NOUN	O	I-Entity
.	PUNCT	O	O

Hyperalgesia	PROPN	O	I-Entity
and	CCONJ	O	O
myoclonus	NOUN	O	I-Entity
in	ADP	O	O
terminal	NOUN	O	O
cancer	NOUN	O	I-Entity
patients	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
continuous	ADJ	O	O
intravenous	ADJ	O	O
morphine	NOUN	O	I-Entity
.	PUNCT	O	O

-DOCSTART- (19719056)

On	ADP	O	O
transthoracic	NOUN	O	O
echocardiogram	NOUN	O	O
,	PUNCT	O	O
she	PRON	O	O
had	VERB	O	O
moderate	ADJ	O	O
left	VERB	O	B-Entity
ventricular	ADJ	O	I-Entity
dysfunction	NOUN	O	I-Entity
with	ADP	O	O
regional	ADJ	O	O
variability	NOUN	O	O
and	CCONJ	O	O
moderate	ADJ	O	O
mitral	ADJ	O	B-Entity
regurgitation	NOUN	O	I-Entity
.	PUNCT	O	O

Heparin	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
thrombocytopenia	NOUN	O	I-Entity
presents	NOUN	O	O
5	NUM	O	O
to	PART	O	O
12	NUM	O	O
days	NOUN	O	O
after	ADP	O	O
heparin	NOUN	O	I-Entity
exposure	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
or	CCONJ	O	O
without	ADP	O	O
arterial	NOUN	O	B-Entity
or	CCONJ	O	I-Entity
venous	ADJ	O	I-Entity
thromboemboli	NOUN	O	I-Entity
.	PUNCT	O	O

Delayed	ADJ	O	O
recognition	NOUN	O	O
and	CCONJ	O	O
treatment	NOUN	O	O
of	ADP	O	O
heparin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
thrombocytopenia	NOUN	O	I-Entity
contribute	VERB	O	O
to	ADP	O	O
poor	ADJ	O	O
patient	ADJ	O	O
outcomes	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
suggested	VERB	O	O
that	ADP	O	O
KF17837	PROPN	O	I-Entity
is	VERB	O	O
a	DET	O	O
centrally	ADV	O	O
active	ADJ	O	O
adenosine	NOUN	O	I-Entity
A2A	PROPN	O	O
receptor	NOUN	O	O
antagonist	NOUN	O	O
and	CCONJ	O	O
that	ADP	O	O
the	DET	O	O
dopaminergic	ADJ	O	O
function	NOUN	O	O
of	ADP	O	O
the	DET	O	O
nigrostriatal	ADJ	O	O
pathway	NOUN	O	O
is	VERB	O	O
potentiated	VERB	O	O
by	ADP	O	O
adenosine	NOUN	O	I-Entity
A2A	ADJ	O	O
receptor	NOUN	O	O
antagonists	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
results	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
fluvoxamine	NOUN	O	I-Entity
given	VERB	O	O
repeatedly	ADV	O	O
acts	NOUN	O	O
differently	ADV	O	O
than	ADP	O	O
citalopram	NOUN	O	I-Entity
,	PUNCT	O	O
another	DET	O	O
selective	ADJ	O	O
serotonin	NOUN	O	I-Entity
uptake	NOUN	O	O
inhibitor	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
differs	VERB	O	O
also	ADV	O	O
from	ADP	O	O
other	ADJ	O	O
antidepressant	NOUN	O	O
drugs	NOUN	O	O
.	PUNCT	O	O

Aspirin	PROPN	O	I-Entity
(	PUNCT	O	O
acetylsalicylic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
[	PUNCT	O	O
ASA	PROPN	O	I-Entity
]	PUNCT	O	O
)	PUNCT	O	O
,	PUNCT	O	O
an	DET	O	O
irreversible	ADJ	O	O
cyclooxygenase	NOUN	O	O
1	NUM	O	O
and	CCONJ	O	O
2	NUM	O	O
inhibitor	NOUN	O	O
,	PUNCT	O	O
induces	VERB	O	O
developmental	ADJ	O	B-Entity
anomalies	NOUN	O	I-Entity
when	ADV	O	O
administered	VERB	O	O
to	ADP	O	O
Wistar	PROPN	O	O
rats	NOUN	O	O
on	ADP	O	O
gestational	ADJ	O	O
day	NOUN	O	O
(	PUNCT	O	O
GD	PROPN	O	O
)	PUNCT	O	O
9	NUM	O	O
,	PUNCT	O	O
10	NUM	O	O
,	PUNCT	O	O
or	CCONJ	O	O
11	NUM	O	O

Extended	ADJ	O	O
follow	NOUN	O	O
-	PUNCT	O	O
up	PART	O	O
studies	NOUN	O	O
of	ADP	O	O
up	ADP	O	O
to	PART	O	O
8	NUM	O	O
years	NOUN	O	O
have	VERB	O	O
demonstrated	VERB	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
persistence	NOUN	O	O
of	ADP	O	O
apomorphine	NOUN	O	I-Entity
efficacy	NOUN	O	O
.	PUNCT	O	O

Twenty	NUM	O	O
-	PUNCT	O	O
five	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
rheumatoid	ADJ	O	B-Entity
arthritis	NOUN	O	I-Entity
(	PUNCT	O	O
RA	PROPN	O	I-Entity
)	PUNCT	O	O
who	NOUN	O	O
developed	VERB	O	O
toxicity	NOUN	O	I-Entity
while	ADP	O	O
taking	VERB	O	O
remission	NOUN	O	O
inducing	VERB	O	O
drugs	NOUN	O	O
and	CCONJ	O	O
30	NUM	O	O
without	ADP	O	O
toxicity	NOUN	O	I-Entity
were	VERB	O	O
studied	VERB	O	O
for	ADP	O	O
possible	ADJ	O	O
associations	NOUN	O	O
with	ADP	O	O
class	NOUN	O	O
I	PRON	O	O
and	CCONJ	O	O
II	PROPN	O	O
HLA	PROPN	O	O
antigens	NOUN	O	O
.	PUNCT	O	O

Compared	VERB	O	O
to	ADP	O	O
healthy	ADJ	O	O
controls	NOUN	O	O
a	DET	O	O
lower	ADJ	O	O
DR5	PROPN	O	O
frequency	NOUN	O	O
was	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
RA	PROPN	O	I-Entity
except	ADP	O	O
for	ADP	O	O
the	DET	O	O
Tiopronin	PROPN	O	I-Entity
related	VERB	O	O
nephritis	NOUN	O	I-Entity
group	NOUN	O	O
.	PUNCT	O	O

NGF	PROPN	O	O
and	CCONJ	O	O
PGs	PROPN	O	I-Entity
in	ADP	O	O
the	DET	O	O
bladder	NOUN	O	O
can	VERB	O	O
be	VERB	O	O
affected	VERB	O	O
by	ADP	O	O
pathological	ADJ	O	O
changes	NOUN	O	O
in	ADP	O	O
the	DET	O	O
bladder	NOUN	O	O
and	CCONJ	O	O
these	DET	O	O
changes	NOUN	O	O
can	VERB	O	O
be	VERB	O	O
detected	VERB	O	O
in	ADP	O	O
urine	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
OAB	PROPN	O	I-Entity
urinary	ADJ	O	O
PGE2	PROPN	O	I-Entity
positively	ADV	O	O
correlated	VERB	O	O
with	ADP	O	O
volume	NOUN	O	O
at	ADP	O	O
first	ADJ	O	O
desire	NOUN	O	O
to	PART	O	O
void	VERB	O	O
and	CCONJ	O	O
maximum	VERB	O	O
cystometric	ADJ	O	O
capacity	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
<	X	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Pretreatment	NOUN	O	O
with	ADP	O	O
dexamethasone	NOUN	O	I-Entity
is	VERB	O	O
not	ADV	O	O
justified	VERB	O	O
to	PART	O	O
prevent	VERB	O	O
postoperative	ADJ	O	B-Entity
myalgia	NOUN	O	I-Entity
after	ADP	O	O
succinylcholine	NOUN	O	I-Entity
.	PUNCT	O	O

-DOCSTART- (12091028)

A	DET	O	O
technique	NOUN	O	O
of	ADP	O	O
continuous	ADJ	O	O
intravenous	ADJ	O	O
anaesthesia	NOUN	O	O
with	ADP	O	O
ketamine	NOUN	O	I-Entity
was	VERB	O	O
used	VERB	O	O
successfully	ADV	O	O
during	ADP	O	O
the	DET	O	O
Somalia	PROPN	O	O
civil	ADJ	O	O
war	NOUN	O	O
in	ADP	O	O
1994	NUM	O	O
and	CCONJ	O	O
in	ADP	O	O
north	NOUN	O	O
Uganda	PROPN	O	O
in	ADP	O	O
1999	NUM	O	O
for	ADP	O	O
64	NUM	O	O
operations	NOUN	O	O
in	ADP	O	O
62	NUM	O	O
patients	NOUN	O	O
,	PUNCT	O	O
aged	VERB	O	O
from	ADP	O	O
6	NUM	O	O
weeks	NOUN	O	O
to	ADP	O	O
70	NUM	O	O
years	NOUN	O	O
,	PUNCT	O	O
undergoing	VERB	O	O
limb	NOUN	O	O
and	CCONJ	O	O
abdominal	ADJ	O	O
surgery	NOUN	O	O
including	VERB	O	O
caesarian	ADJ	O	O
sections	NOUN	O	O
and	CCONJ	O	O
interventions	NOUN	O	O
in	ADP	O	O
neonates	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
mechanism	NOUN	O	O
by	ADP	O	O
which	ADJ	O	O
this	DET	O	O
endogenous	ADJ	O	O
steroid	NOUN	O	I-Entity
enhances	VERB	O	O
memory	NOUN	O	O
formation	NOUN	O	O
is	VERB	O	O
hypothesized	VERB	O	O
to	PART	O	O
involve	VERB	O	O
actions	NOUN	O	O
on	ADP	O	O
glutamatergic	NOUN	O	O
and	CCONJ	O	O
GABAergic	PROPN	O	O
systems	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
analogs	NOUN	O	O
tested	VERB	O	O
were	VERB	O	O
:	PUNCT	O	O
11-ketopregnenolone	NUM	O	B-Entity
sulphate	NOUN	O	I-Entity
(	PUNCT	O	O
an	DET	O	O
agent	NOUN	O	O
that	ADJ	O	O
is	VERB	O	O
inactive	ADJ	O	O
at	ADP	O	O
GABA(A)Rs	PROPN	O	I-Entity
and	CCONJ	O	O
NMDARs	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
epipregnanolone	NOUN	O	B-Entity
(	PUNCT	O	I-Entity
[	PUNCT	O	I-Entity
3beta	NUM	O	I-Entity
-	PUNCT	O	I-Entity
hydroxy-5beta	NUM	O	I-Entity
-	PUNCT	O	I-Entity
pregnan-20-one	NOUN	O	I-Entity
]	PUNCT	O	I-Entity
sulphate	NOUN	O	I-Entity
,	PUNCT	O	O
an	DET	O	O
inhibitor	NOUN	O	O
of	ADP	O	O
both	DET	O	O
GABA(A)Rs	PROPN	O	I-Entity
and	CCONJ	O	O
NMDARs	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
newly	ADV	O	O
synthesized	VERB	O	O
(	PUNCT	O	O
-	PUNCT	O	O
)	PUNCT	O	O

-DOCSTART- (11752998)

These	DET	O	O
results	NOUN	O	O
show	VERB	O	O
selective	ADJ	O	O
inhibition	NOUN	O	O
by	ADP	O	O
intrathecal	ADJ	O	O
adenosine	NOUN	O	I-Entity
of	ADP	O	O
hypersensitivity	NOUN	O	I-Entity
,	PUNCT	O	O
presumed	VERB	O	O
to	PART	O	O
reflect	VERB	O	O
central	ADJ	O	O
sensitization	NOUN	O	O
in	ADP	O	O
humans	NOUN	O	O
after	ADP	O	O
peripheral	ADJ	O	O
capsaicin	NOUN	O	I-Entity
injection	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
the	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
assess	VERB	O	O
the	DET	O	O
contribution	NOUN	O	O
of	ADP	O	O
the	DET	O	O
glycine	NOUN	O	I-Entity
site	NOUN	O	O
of	ADP	O	O
NMDA	PROPN	O	I-Entity
receptors	NOUN	O	O
in	ADP	O	O
the	DET	O	O
striatum	NOUN	O	O
to	ADP	O	O
the	DET	O	O
regulation	NOUN	O	O
of	ADP	O	O
muscle	NOUN	O	O
tone	NOUN	O	O
.	PUNCT	O	O

-DOCSTART- (7053705)

Dexmedetomidine	PROPN	O	I-Entity
,	PUNCT	O	O
acting	VERB	O	O
through	ADP	O	O
central	ADJ	O	O
alpha-2	ADJ	O	O
adrenoceptors	NOUN	O	O
,	PUNCT	O	O
prevents	VERB	O	O
opiate	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
muscle	NOUN	O	B-Entity
rigidity	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
rat	NOUN	O	O
.	PUNCT	O	O

Two	NUM	O	O
elderly	ADJ	O	O
patients	NOUN	O	O
with	ADP	O	O
a	DET	O	O
history	NOUN	O	O
of	ADP	O	O
either	DET	O	O
cerebral	ADJ	O	B-Entity
vascular	ADJ	O	I-Entity
accident	NOUN	O	I-Entity
(	PUNCT	O	O
CVA	PROPN	O	I-Entity
)	PUNCT	O	O
or	CCONJ	O	O
head	NOUN	O	B-Entity
trauma	NOUN	O	I-Entity
and	CCONJ	O	O
no	DET	O	O
evidence	NOUN	O	O
of	ADP	O	O
renal	ADJ	O	B-Entity
disease	NOUN	O	I-Entity
developed	VERB	O	O
seizures	NOUN	O	I-Entity
while	ADP	O	O
receiving	VERB	O	O
maximum	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
imipenem	NOUN	O	B-Entity
/	SYM	O	I-Entity
cilastatin	NOUN	O	I-Entity
.	PUNCT	O	O

All	DET	O	O
seizures	NOUN	O	I-Entity
were	VERB	O	O
controlled	VERB	O	O
with	ADP	O	O
therapeutic	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
phenytoin	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
extent	NOUN	O	O
of	ADP	O	O
neuronal	ADJ	O	B-Entity
injury	NOUN	O	I-Entity
was	VERB	O	O
determined	VERB	O	O
by	ADP	O	O
2,3,5-triphenyltetrazolium	NUM	O	I-Entity
staining	NOUN	O	O
.	PUNCT	O	O

Response	NOUN	O	O
to	ADP	O	O
Varidase	PROPN	O	O
skin	NOUN	O	O
test	NOUN	O	O
antigen	NOUN	O	O
was	VERB	O	O
negative	ADJ	O	O
for	ADP	O	O
all	DET	O	O
eight	NUM	O	O
tuberculosis	NOUN	O	I-Entity
patients	NOUN	O	O
tested	VERB	O	O
,	PUNCT	O	O
but	CCONJ	O	O
there	ADV	O	O
occurred	VERB	O	O
a	DET	O	O
hyper	ADJ	O	O
-	PUNCT	O	O
responsiveness	NOUN	O	O
of	ADP	O	O
the	DET	O	O
lymphocytes	NOUN	O	O
of	ADP	O	O
these	DET	O	O
eight	NUM	O	O
patients	NOUN	O	O
to	ADP	O	O
phytomitogen	NOUN	O	O
(	PUNCT	O	O
PHA	PROPN	O	O
-	PUNCT	O	O
P	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Chlorthalidone	PROPN	O	I-Entity
(	PUNCT	O	O
50	NUM	O	O
mg	NUM	O	O
daily	ADV	O	O
)	PUNCT	O	O
was	VERB	O	O
given	VERB	O	O
for	ADP	O	O
14	NUM	O	O
days	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
this	DET	O	O
study	NOUN	O	O
we	PRON	O	O
postulated	VERB	O	O
that	ADP	O	O
during	ADP	O	O
acute	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
gentamicin	VERB	O	I-Entity
the	DET	O	O
transient	ADJ	O	O
or	CCONJ	O	O
dynamic	ADJ	O	O
response	NOUN	O	O
of	ADP	O	O
blood	NOUN	O	O
vessels	NOUN	O	O
could	VERB	O	O
be	VERB	O	O
affected	VERB	O	O
,	PUNCT	O	O
and	CCONJ	O	O
that	DET	O	O
antioxidants	NOUN	O	O
can	VERB	O	O
prevent	VERB	O	O
the	DET	O	O
changes	NOUN	O	O
in	ADP	O	O
dynamic	ADJ	O	O
responses	NOUN	O	O
of	ADP	O	O
blood	NOUN	O	O
vessels	NOUN	O	O
.	PUNCT	O	O

-DOCSTART- (15096016)

-DOCSTART- (12734532)

Activation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
nuclear	ADJ	O	O
enzyme	NOUN	O	O
poly(ADP	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
ribose	NOUN	O	I-Entity
)	PUNCT	O	I-Entity
polymerase	NOUN	O	O
(	PUNCT	O	O
PARP	PROPN	O	O
)	PUNCT	O	O
by	ADP	O	O
oxidant	NOUN	O	O
-	PUNCT	O	O
mediated	VERB	O	O
DNA	NOUN	O	O
damage	NOUN	O	O
is	VERB	O	O
an	DET	O	O
important	ADJ	O	O
pathway	NOUN	O	O
of	ADP	O	O
cell	NOUN	O	O
dysfunction	NOUN	O	O
and	CCONJ	O	O
tissue	NOUN	O	O
injury	NOUN	O	O
in	ADP	O	O
conditions	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
oxidative	ADJ	O	O
stress	NOUN	O	O
.	PUNCT	O	O

-DOCSTART- (11302406)

Fluconazole	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
torsade	NOUN	O	B-Entity
de	X	O	I-Entity
pointes	NOUN	O	I-Entity
.	PUNCT	O	O

-DOCSTART- (11058428)

Because	ADP	O	O
of	ADP	O	O
the	DET	O	O
National	PROPN	O	O
Acute	PROPN	O	O
Spinal	PROPN	O	B-Entity
Cord	PROPN	O	I-Entity
Injury	PROPN	O	I-Entity
Studies	PROPN	O	O
(	PUNCT	O	O
NASCIS	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
high	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
methylprednisolone	NOUN	O	I-Entity
became	VERB	O	O
the	DET	O	O
standard	NOUN	O	O
of	ADP	O	O
care	NOUN	O	O
for	ADP	O	O
the	DET	O	O
acute	ADJ	O	O
spinal	ADJ	O	B-Entity
cord	NOUN	O	I-Entity
injury	NOUN	O	I-Entity
.	PUNCT	O	O

-DOCSTART- (11022397)

Scopolamine	NOUN	O	I-Entity
was	VERB	O	O
used	VERB	O	O
as	ADP	O	O
a	DET	O	O
positive	ADJ	O	O
control	NOUN	O	O
to	PART	O	O
detect	VERB	O	O
age	NOUN	O	O
-	PUNCT	O	O
dependent	ADJ	O	O
changes	NOUN	O	O
in	ADP	O	O
central	ADJ	O	O
cholinergic	ADJ	O	O
functioning	NOUN	O	O
in	ADP	O	O
the	DET	O	O
elderly	ADJ	O	O
.	PUNCT	O	O

Acute	PROPN	O	O
confusion	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
acetazolamide	NOUN	O	I-Entity
is	VERB	O	O
a	DET	O	O
well	ADV	O	O
known	VERB	O	O
adverse	ADJ	O	O
drug	NOUN	O	O
reaction	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
renal	ADJ	O	B-Entity
impairment	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
a	DET	O	O
female	ADJ	O	O
patient	NOUN	O	O
with	ADP	O	O
a	DET	O	O
diagnosis	NOUN	O	O
of	ADP	O	O
a	DET	O	O
not	ADV	O	O
otherwise	ADV	O	O
specified	VERB	O	O
psychotic	ADJ	O	B-Entity
disorder	NOUN	O	I-Entity
(	PUNCT	O	O
DSM	PROPN	O	O
-	PUNCT	O	O
IV	PROPN	O	O
)	PUNCT	O	O
who	NOUN	O	O
developed	VERB	O	O
hypomania	NOUN	O	I-Entity
shortly	ADV	O	O
after	ADP	O	O
the	DET	O	O
introduction	NOUN	O	O
of	ADP	O	O
olanzapine	ADJ	O	I-Entity
treatment	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
demonstrate	VERB	O	O
a	DET	O	O
neutrophil	ADJ	O	O
defect	NOUN	O	O
in	ADP	O	O
ALF	PROPN	O	I-Entity
due	ADP	O	O
to	ADP	O	O
paracetamol	NOUN	O	I-Entity
overdose	NOUN	O	I-Entity
,	PUNCT	O	O
that	DET	O	O
is	VERB	O	O
complement	ADJ	O	O
dependent	ADJ	O	O
but	CCONJ	O	O
independent	ADJ	O	O
of	ADP	O	O
serum	NOUN	O	O
complement	NOUN	O	O
,	PUNCT	O	O
possibly	ADV	O	O
connected	VERB	O	O
to	ADP	O	O
the	DET	O	O
complement	NOUN	O	O
receptor	NOUN	O	O
.	PUNCT	O	O

Three	NUM	O	O
subjects	NOUN	O	O
(	PUNCT	O	O
2	NUM	O	O
on	ADP	O	O
sertraline	NOUN	O	I-Entity
and	CCONJ	O	O
1	NUM	O	O
on	ADP	O	O
placebo	NOUN	O	O
)	PUNCT	O	O
withdrew	VERB	O	O
from	ADP	O	O
the	DET	O	O
study	NOUN	O	O
because	ADP	O	O
of	ADP	O	O
side	NOUN	O	O
effects	NOUN	O	O
.	PUNCT	O	O

Case	NOUN	O	O
report	NOUN	O	O
:	PUNCT	O	O
pentamidine	NOUN	O	I-Entity
and	CCONJ	O	O
polymorphic	VERB	O	O
ventricular	ADJ	O	B-Entity
tachycardia	NOUN	O	I-Entity
revisited	VERB	O	O
.	PUNCT	O	O

-DOCSTART- (7710775)

Induction	NOUN	O	O
of	ADP	O	O
the	DET	O	O
obstructive	ADJ	O	B-Entity
sleep	NOUN	O	I-Entity
apnea	NOUN	O	I-Entity
syndrome	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
woman	NOUN	O	O
by	ADP	O	O
exogenous	ADJ	O	O
androgen	NOUN	O	I-Entity
administration	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
rechallenge	NOUN	O	O
with	ADP	O	O
androgen	NOUN	O	I-Entity
produced	VERB	O	O
symptoms	NOUN	O	O
of	ADP	O	O
obstructive	ADJ	O	B-Entity
sleep	NOUN	O	I-Entity
apnea	NOUN	O	I-Entity
that	ADJ	O	O
abated	VERB	O	O
upon	ADP	O	O
withdrawal	NOUN	O	O
of	ADP	O	O
the	DET	O	O
hormone	NOUN	O	O
.	PUNCT	O	O

Effect	PROPN	O	O
of	ADP	O	O
captopril	NOUN	O	I-Entity
on	ADP	O	O
pre	NOUN	O	O
-	PUNCT	O	O
existing	VERB	O	O
and	CCONJ	O	O
aminonucleoside	ADV	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
proteinuria	NOUN	O	I-Entity
in	ADP	O	O
spontaneously	ADV	O	O
hypertensive	ADJ	O	I-Entity
rats	NOUN	O	O
.	PUNCT	O	O

-DOCSTART- (2886572)

Forty	NUM	O	O
-	PUNCT	O	O
four	NUM	O	O
percent	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
uveitis	NOUN	O	I-Entity
had	VERB	O	O
one	NUM	O	O
or	CCONJ	O	O
more	ADV	O	O
identifiable	ADJ	O	O
signs	NOUN	O	O
or	CCONJ	O	O
symptoms	NOUN	O	O
,	PUNCT	O	O
such	ADJ	O	O
as	ADP	O	O
red	ADJ	O	O
eye	NOUN	O	O
,	PUNCT	O	O
ocular	ADJ	O	B-Entity
pain	NOUN	O	I-Entity
,	PUNCT	O	O
decreased	VERB	O	B-Entity
visual	ADJ	O	I-Entity
acuity	NOUN	O	I-Entity
,	PUNCT	O	O
or	CCONJ	O	O
photophobia	NOUN	O	I-Entity
,	PUNCT	O	O
in	ADP	O	O
order	NOUN	O	O
of	ADP	O	O
decreasing	VERB	O	O
frequency	NOUN	O	O
.	PUNCT	O	O

